



Statistical Analysis Plan

SAP Text Version Number: 2.0

SAP Text Date: 22-Apr-2025

Sponsor Name: Apnimed, Inc.

Protocol Number: APC-APN-305

Protocol Title: Phase 3 Randomized Double-Blind Placebo-Controlled 6-Month Parallel-Arm Study to Compare a Fixed Dose Combination of Aroxypytynin/Atomoxetine (AD109) to Placebo in Obstructive Sleep Apnea (Protocol# APC-APN-305, SynAIRgy Study)

Protocol Version and Date: V6.0, 17-Apr-2025

Syneos Health Project Code: 7041290

Authors:

Shuhong Zhao, Ph.D., Sr. Principal Biostatistician

Notice of Confidential and Proprietary Information:

The information contained in this document is confidential belonging to Apnimed, Inc.. Acceptance of this document constitutes agreement by the recipient that no information contained herein will be published or disclosed without prior written authorization from an official of Apnimed, Inc.. However, this document may be disclosed to appropriate Institutional Review Board and Ethics Committees or duly authorized representatives of a national regulatory authority under the condition that they are requested to keep it confidential. In the event of an actual or suspected breach of this obligation, Syneos Health should be notified promptly.



This document is confidential.

Revision History

Version #	Date (DD-Mmm-YYYY)	Document Owner	Revision Summary
1.0	17-Apr-2025	Shuhong Zhao	Initial Release Version
2.0	22-Apr-2025	Shuhong Zhao	1. Adjusted visit windows in section 6.4 to account for out of window visits 2. Clarified language of the supportive analysis using the PPS-A analysis set in section 8.2.3 3. Added definition of baseline for vital signs collected in the evening and morning of PSG visits in section 9.3 4. Specified use of nominal visit for ECG summaries in section 9.4 5. Added an exploratory analysis of AHI4 to assess the relative change on the log scale in section 8.1

This document is confidential.

I confirm that I have reviewed this document and agree with the content.

Approvals		
Syneos Health Approval		
Shuhong Zhao, PhD Sr. Principal Biostatistician		Electronically signed by: Shuhong Zhao Reason: I am the author Date: Apr 22, 2025 14:45 EDT
Name, Title Lead Biostatistician	Signature	Date (DD-Mmm-YYYY)
Jianping He Sr. Principal Biostatistician		Electronically signed by: Jianping He Reason: I am the reviewer Date: Apr 22, 2025 15:09 EDT
Name, Title Senior Reviewing Biostatistician	Signature	Date (DD-Mmm-YYYY)
Apnimed Approval		
Ron Farkas, MD Chief Medical Officer		Electronically signed by: Ron Farkas Reason: I am the approver Date: Apr 22, 2025 15:41 EDT
Name, Title Sponsor Contact	Signature	Date (DD-Mmm-YYYY)
Luigi Taranto Montemurro, MD Chief Scientific Officer		Electronically signed by: Luigi Taranto Montemurro Reason: I am the approver Date: Apr 22, 2025 15:51 EDT
Name, Title Sponsor Contact	Signature	Date (DD-Mmm-YYYY)
Brian Mangal, MSc. Statistical Consultant		Electronically signed by: Brian Mangal Reason: I am the approver Date: Apr 22, 2025 12:39 PDT
Name, Title Sponsor Contact	Signature	Date (DD-Mmm-YYYY)

This document is confidential.

Table of Contents

Revision History.....	2
Approvals	3
1. Glossary of Abbreviations	7
2. Purpose	10
2.1. Responsibilities	10
2.2. Timings of Analyses	10
3. Study Objectives, Endpoints and Estimands	11
4. Study Details/Design	16
4.1. Brief Description	16
4.2. Determination of Sample Size.....	17
4.3. Treatment Assignment and Blinding	18
5. Analysis Sets	20
5.1. Screened Set.....	20
5.2. Enrolled Set.....	20
5.3. Primary Full Analysis Set	20
5.4. Full Analysis Set	20
5.5. Modified Intent to Treat Set.....	20
5.6. Safety Set.....	20
5.7. Per Protocol Set.....	20
6. General Aspects for Statistical Analysis.....	22
6.1. General Methods	22
6.2. Key Definitions.....	22
6.2.1. Coding Dictionaries.....	22
6.2.2. Study Day.....	23
6.2.3. AHI4 Strata.....	23
6.2.4. Randomization Strata.....	23
6.2.5. Baseline.....	23
6.2.6. Change and Percent Change from Baseline.....	23

This document is confidential.

6.2.7.	Study Completion.....	23
6.2.8.	Duration of Treatment.....	24
6.2.9.	Treatment Emergent AEs (TEAEs)	24
6.3.	Missing Data	24
6.4.	Visit Windows	27
6.5.	Pooling of Centers	29
6.6.	Outliers	29
6.7.	Sub-groups	29
6.8.	Multiplicity	29
7.	Demographic, Other Baseline Characteristics and Medication	31
7.1.	Participant Disposition and Withdrawals	31
7.2.	Protocol Deviations	31
7.3.	Demographic and Baseline Characteristics.....	31
7.4.	Medical History and Concomitant Diseases	32
7.5.	Medications	32
7.5.1.	Prior/Concomitant Medication.....	32
7.6.	Medical Device Use	33
7.7.	Prior and Concomitant Medical or Surgical Procedure	34
7.8.	Extent of Exposure	34
7.9.	Treatment Compliance.....	34
8.	Efficacy	36
8.1.	Primary Efficacy Estimand(s)/Endpoint(s) and Analysis	36
8.2.	Key Secondary Efficacy Estimand(s)/Endpoint(s) and Analysis	40
8.2.1.	Definition of the Continuous Key Secondary Efficacy Endpoints.....	41
8.2.2.	Analyses of the Continuous Key Secondary Efficacy Endpoints	41
8.2.3.	Proportion of Participants with $\geq 50\%$ Reduction in AHI4 at Week 26.....	42
8.3.	Other Secondary Efficacy Endpoints and Analyses	45
8.3.1.	Definition of the Secondary Efficacy Endpoints	45
8.3.2.	Analyses of the Secondary Efficacy Endpoints.....	46

This document is confidential.

8.4.	Exploratory Efficacy Endpoints and Analyses	46
9.	Safety.....	52
9.1.	Adverse Events / Adverse Drug Reactions	52
9.2.	Laboratory Evaluations	53
9.3.	Vital Signs.....	55
9.4.	ECG.....	56
9.5.	Physical Examination.....	57
9.6.	Other Safety	58
10.	Interim Analyses.....	62
11.	Changes from Analysis Planned in Protocol	63
12.	Reference List.....	64
13.	Programming Considerations	65
14.	Quality Control.....	66
15.	Example SAS Code for the Primary and Key Secondary Endpoint Analyses.....	67
15.1.	Imputation Procedures.....	67
15.1.1.	Non-monotone missing imputation.....	67
15.1.2.	Monotone Missing imputation	67
15.2.	Analysis Procedure.....	69
16.	Example SAS Code for AHI4 Responder.....	70
16.1.	Imputation Procedures.....	70
16.1.1.	Non-monotone missing imputation.....	70
16.1.2.	Monotone Missing imputation	70
16.2.	Analysis Procedure.....	70
17.	Appendix 1: Adverse Event of Special Interest List of FMQs and PTs	73

This document is confidential.

1. Glossary of Abbreviations

Abbreviation	Description
ABPM	Ambulatory blood pressure monitoring
AE	Adverse Event
AHI	apnea-hypopnea index
AHI3a	apnea-hypopnea index based on 3% hypopnea desaturation plus arousals
AHI4	apnea-hypopnea index based on 4% hypopnea desaturation
ATC	Anatomical Therapeutic Chemical
ALT	alanine aminotransferase
AROX	aroxybutynin
AST	aspartate aminotransferase
ATO	atomoxetine
BDRM	Blinded Data Review Meeting
BMI	Body Mass index
BUN	Blood urea nitrogen
CI	Confidence Interval
CMH	Cochran-Mantel Haenszel
CRF	Case Report Form
CSR	Clinical study report
DMC	Data Monitoring Committee
DSST	Digit Symbol Substitution Test
ECG	Electrocardiogram
eCRF	Electronic case report form
EOS	End of Study
ESS	Epworth Sleepiness Scale
FAS	Full Analysis Set
FMQs	FDA Medical Queries
FSH	follicle stimulating hormone
GLP-1	Glucagon-like peptide-1
HB4	hypoxic burden based on 4% hypopnea desaturation
HbA1c	hemoglobin A1c (glycated hemoglobin)
hCG	human chorionic gonadotropin
ICF	Informed Consent Form
ICH	International Conference on Harmonization

This document is confidential.

Abbreviation	Description
IMP	Investigational medicinal product
IRT	Interactive Response Technology
LOCF	Last Observation Carried Forward
MAR	Missing at Random
MADRS-S	Self-reported Montgomery-Asberg depression rating scale
M-CSSA	Modified cocaine selective severity assessment
MedDRA	Medical Dictionary for Regulatory Activities
MITT	Modified Intent to Treat
MNAR	Missing not at Random
MWPC	Meaning Within Patient Change
NREM	Non-rapid eye movement
ODI3	Oxygen desaturation index based on 3% hypopnea desaturation
OSA	Obstructive Sleep Apnea
PAP	Positive Airway Pressure
PFAS	Primary Full Analysis Set
PGI-C	Patient Global Impression - Change
PGI-S	Patient Global impression Severity
PPS-A	Per-Protocol Set for AHI4
PPS-P	Per-Protocol Set for PROMIS-Fatigue
PRO	Patient Reported Outcome
PROMIS	Patient Reported Outcomes Measurement Information System
PSG	Polysomnogram
PT	Preferred Term
PVT	Psychomotor Vigilance Test
RBC	Red blood cell count
REM	Rapid eye movement
QTc	Corrected QT Interval
QTcF	Corrected QT Interval Fridericia
SAE	Serious Adverse Event
SAP	Statistical Analysis Plan
SD	Standard Deviation
SI	Standard International System of Units
SoA	Schedule of Activities
SOC	System Organ Class
SOP	Standard Operating Procedure

This document is confidential.

Abbreviation	Description
Spielberger	Short version of Spielberger state-trait anxiety inventory
SS	Safety Set
STAI	Spielberger Anxiety Inventory – Short Form
TEAE	Treatment-Emergent Adverse Event
TFL	Table, Figure and Listing
TIA	Transient Ischemic Attack
TST	Total sleep time
VLT	Verbal learning task
WBC	White blood cell
WHO	World Health Organization
WOCBP	Women of childbearing potential

This document is confidential.

2. Purpose

This statistical analysis plan (SAP) outlines the statistical methods for the display, summary and analysis of data collected within the scope of Protocol APC-APN-305. The purpose of this plan is to provide general guidelines from which the analysis will proceed. Deviations from these guidelines will be substantiated by sound statistical rationale and will be documented in the clinical study report (CSR). If there are differences between the protocol and the SAP, this SAP will take precedence.

The SAP should be read in conjunction with the study protocol and the case report forms (CRFs). This version of the SAP has been developed using the version of the protocol mentioned above.

2.1. Responsibilities

Syneos Health will perform the statistical analyses and is responsible for the production and quality control of all tables, figures, and listings.

2.2. Timings of Analyses

Final Analysis: The primary analysis of safety and efficacy is planned after all participants complete the final study visit or terminate early from the study.

Data Monitoring Committee (DMC) Analysis: For this study, DMC analyses will be performed for the independent DMC to review the accumulated safety data, participant disposition and limited efficacy data after approximately 50 participants have completed at least 3 months of study drug therapy and every 3 months thereafter through the end of the study. Further description of the DMC analyses can be found in the most recent version of the DMC charter. An unblinded team from Syneos Health Biostatistics will perform the analyses as described in Section 4.4 of this SAP to maintain the blinding of the study.

Interim Analysis: No interim analysis is planned for this the study.

This document is confidential.

3. Study Objectives, Endpoints and Estimands

Objectives	Endpoints/Assessments
Primary Objective Compare efficacy on airway obstruction of AD109 vs placebo in participants with mild to severe OSA not taking Glucagon-like peptide-1(GLP-1) agonists for weight loss	Primary Endpoint Change from baseline in apnea-hypopnea index based on 4% hypopnea desaturation (AHI4) at week 26
Secondary Objectives Compare efficacy on OSA symptoms and oxygenation of AD109 vs placebo in participants with mild to severe OSA not taking GLP-1 agonists for weight loss	Key Secondary Endpoints - Change from baseline in ODI3 at week 26 - Change from baseline in PROMIS-Fatigue at week 26 - Relative change from baseline in HB4 (based on natural log scale) at week 26 - Change from baseline in PROMIS-Sleep Impairment at week 26 - Proportion of participants with $\geq 50\%$ reduction in AHI4 at 26 weeks Secondary Endpoints - Change from baseline in PGI-S for Fatigue at week 26 - PGI-C for fatigue at week 26 - Change from baseline in ESS at week 26

This document is confidential.

Exploratory Objectives Examine effects of AD109 on PSG sleep parameters, additional measures of airway obstruction, and at additional time points, in participants with mild to severe OSA not taking GLP-1 agonists for weight loss	Exploratory Endpoints • Sleep architecture and sleep stage distribution at 4 and 26 weeks • Above listed endpoints (Primary and Secondary) at 4 weeks (where applicable) • Percent of participants with AHI4<15, <10 and <5 at 4 and 26 weeks • Proportion of participants with AHI4 reduction of $\geq 30\%$ to $\geq 90\%$ by 10% increments • Change from baseline in AHI3a, HB3a and ODI4 at 4 and 26 weeks, as applicable • Change from baseline in Non-Rapid Eye Movement Apnea-Hypopnea Index [NREM AHI] at 4 and 26 weeks • Change from baseline in Rapid Eye Movement Apnea-Hypopnea Index [REM AHI] at 4 and 26 weeks (excluding participants whose PSG has <10 minutes of REM sleep) • Change from baseline in supine AHI4 [AHI4S] at 4 and 26 weeks (excluding participants whose PSG has <10 minutes of supine sleep) • Change from baseline in: Total sleep time (TST) and percentage of TST in sleep stages (sleep efficiency [SE]; wake after sleep onset [WASO]; sleep onset latency [SOL]; Stage N1% [N1P], Stage N2% [N2P], Stage N3% [N3P], Stage R% [RP]) • Change from baseline in: Arousal Indices (Arousal Index - Respiratory [ARIR]; Arousal Index - total [ARI]) • Change from baseline to 4 weeks in OSA severity category (None, Mild, Moderate and Severe)
---	---

This document is confidential.

Objectives	Endpoints/Assessments
	Proportion of participants with loud breaths (i.e., snoring)
Safety Objectives Evaluate the safety and tolerability of treatment with AD109 in participants with mild to severe OSA who are not taking GLP-1 agonists for weight loss and in a cohort who are taking GLP-1 agonists for weight loss	Safety Assessments - Physical exam, vital signs, clinical laboratory assessment, ECG - Spontaneous adverse events, including during the post-dosing period - DSST - PVT - Verbal learning task - M-CSSA - MADRS-S - Spielberger
Abbreviations: AHI3a = apnea-hypopnea index based on 3% hypopnea desaturation plus arousals; AHI4 = apnea-hypopnea index based on 4% hypopnea desaturation; DSST = Digit Symbol Substitution Test; ECG = electrocardiogram; ESS = Epworth sleepiness Scale; HB4 = hypoxic burden based on 4% hypopnea desaturation; MADRS-S = self-reported Montgomery-Asberg depression rating scale; M-CSSA = Modified cocaine selective severity assessment; ODI3 = oxygen desaturation index based on 3% hypopnea desaturation; OSA = Obstructive Sleep Apnea; PGI-C = patient global impression change; PGI-S = patient global impression severity; PROMIS = Patient Reported Outcomes Measurement Information System; PSG = polysomnography; PVT = psychomotor vigilance test; Spielberger = short version of Spielberger anxiety inventory	

3.1 Primary estimands

The primary clinical question of interest is: what is the treatment effect of AD109 compared with placebo in participants with mild to severe OSA, who are not taking GLP-1 agonists for weight loss, with respect to change from baseline in AHI4 at week 26 (and all secondary endpoints defined on a continuous scale), regardless of adherence to investigational product and irrespective of any changes in background therapy?

This document is confidential.

- Treatment condition: investigational treatment with AD109/Placebo regardless of adherence to investigational product and of any changes in background therapy (treatment policy strategy).
- Variable/endpoint:
 - Primary: change from baseline to week 26 in AHI4
 - Secondary:
 - Change from baseline to week 26 in ODI3, PROMIS-fatigue, HB4, PROMIS sleep impairment, PGI-S for fatigue, ESS and AHI3a
 - PGI-C scores at week 26
- Population of interest: participants with mild to severe OSA not taking GLP-1 agonists for weight loss
- Intercurrent events:
 - Discontinuation of study treatment prior to week 26 due to any reason is handled by the treatment condition (treatment policy strategy).
 - Change in background therapy (i.e., use of PAP or concomitant medications) is handled by the treatment condition (treatment policy strategy)
- Population-level summary measure: Difference in means between AD109 vs placebo estimated using a MMRM.

Rationale for estimand: The primary estimand aims at reflecting how participants with mild to severe OSA, who are not taking GLP-1 agonists for weight loss, are treated in clinical practice and considers both safety and efficacy.

For the secondary endpoint of 50% reduction in AHI4 at week 26 the clinical question of interest is: what is the treatment effect of AD109 compared with placebo in participants with mild to severe OSA who are not taking GLP-1 agonists for weight loss with respect to achieving a 50% reduction in AHI4 at week 26, while on treatment and irrespective of any changes in background therapy?

- Treatment condition: investigational treatment with AD109/Placebo regardless of any changes in background therapy.
- Variable/endpoint: Responder defined as achieving the following 2 criteria:
 - Achieved a $\geq 50\%$ reduction from baseline in AHI4 at week 26
 - Did not discontinue study treatment prior to week 26
- Population of interest: participants with mild to severe OSA not taking GLP-1 agonists for weight loss
- Intercurrent events:

This document is confidential.

- Discontinuation of study treatment prior to week 26 due to any reason is handled by the endpoint definition (composite variable strategy).
 - Change in background therapy (i.e., use of PAP or concomitant medications) is handled by the treatment condition (treatment policy strategy).
- Population-level summary measure: Difference in response rates between AD109 vs placebo estimated using the stratified Cochran-Mantel Haenszel (CMH) approach.

Rationale for estimand: The estimand aims at reflecting how participants with mild to severe OSA, not taking GLP-1 agonists for weight loss, are treated in clinical practice and considers both safety/tolerability and efficacy.

3.2 Supportive estimands

The clinical question of interest for the supportive estimand is: What is the treatment effect of AD109 compared with placebo on primary and secondary endpoints in participants with mild to severe OSA who are not taking GLP-1 agonists for weight loss, when participants are actively on study treatment?

- Treatment condition: AD109 versus placebo while participants remain on the assigned study treatment
- Variable/Endpoint:
 - Primary: change from baseline to week 26 in AHI4
 - Secondary:
 - Change from baseline to week 26 in ODI3, PROMIS-fatigue, HB4, PROMIS sleep impairment, PGI-S for fatigue, ESS and AHI3a
 - PGI-C scores at week 26
- Population of interest: participants with mild to severe OSA not taking GLP-1 agonists for weight loss
- Intercurrent event:
 - Discontinuation of study treatment: Hypothetical strategy - data collected after treatment discontinuation will be excluded from analysis (set to missing).
 - Change in background therapy: Treatment policy strategy - data will be included regardless of changes in PAP use or concomitant medications.
- Population-level summary measure:
 - Difference in adjusted means between AD109 vs placebo estimated using a MMRM.

This document is confidential.

4. Study Details/Design

4.1. Brief Description

The SynAIRgy Study (APC-APN-305) is a randomized, double blind, placebo-controlled, parallel-arm 6 month study of AD109 vs placebo in participants with mild to severe OSA not currently taking GLP-1 agonists, who are intolerant of, or currently refuse, PAP. A screening visit and PSG will be conducted to establish, in combination with patient-reported outcomes assessments (PROs) and other criteria that each participant meets study enrollment criteria. An additional exploratory cohort of up to 100 participants taking a concomitant GLP-1 agonist specifically for weight loss will also be enrolled, randomized 1:1 to AD109 or placebo. These participants will not be included in the primary analysis population.

A screening/baseline PSG is conducted at V2 and is read by the central PSG reading center. For enrollment the AHI4 (hypopneas defined by 4% oxygen desaturation) of the V2 PSG must be >5 , with $\leq 25\%$ central or mixed apneas (as proportion of total apneas + hypopneas), and PLM arousal index ≤ 15 .

Participants who meet all eligibility criteria will be randomized to one of 2 parallel treatment arms. Enrollment within each cohort will be stratified according to baseline AHI4 (<15 , 15 to 30, >30) and PROMIS-Fatigue raw score (<25 vs ≥ 25); to ensure representative distribution of enrollment across strata, the size of strata will be controlled through enrollment limits, with AHI4 <15 representing ~20-40% of participants, AHI4 15 to 30 representing ~20-40% of participants, and AHI4 >30 representing ~20-40% of participants.

The first week of dosing will be with a lower dose of AD109 (run-in) or matched placebo, followed by the target dose taken for the duration of the study.

1. Aroxybutynin 2.5 mg/Atomoxetine 75 mg tablet (n = 320)

- Week 1: aroxybutynin 2.5 mg/atomoxetine 37.5 mg tablet
- Weeks 2-26: aroxybutynin 2.5 mg/atomoxetine 75 mg tablet

2. Placebo tablet (n = 320)

- Week 1: matched placebo tablet
- Weeks 2-26: matched placebo tablet


Dose reduction is not permitted. Dosing is discontinued if the study drug to which the participant is randomized is not tolerated. Note that participants who discontinue dosing are encouraged to continue all other study activities for the full duration of the study.

This document is confidential.

A participant is considered to have completed the study if he/she has completed all phases of the study through the last scheduled procedure shown in the Schedule of Activities (SoA) in the protocol.

A participant is considered to have completed the study if he/she has completed all phases of the study through the last scheduled procedure shown in the Schedule of Activities (SoA) in the protocol.

Figure 1 Overview of Study Design



AROX = *aroxybutynin*; *ATO* = *atomoxetine*; *C* = *contact/call*; *EoS* = *End of Study*; *PSG* = *polysomnogram*; *V* = *visit*

4.2. Determination of Sample Size

A total sample size of approximately 640 participants (320/group) is planned. This sample size is based on the number of participants required to provide at least 90% power for the primary endpoint (change from baseline to week 26 in AHI4) and the key secondary endpoint (change from baseline to week 26 in PROMIS Fatigue T-score).

An additional exploratory cohort of up to 100 participants taking a concomitant GLP-1 agonist specifically for weight loss will also be enrolled, randomized 1:1 to AD109 or placebo. These participants will not be included in the primary analysis population.

Change from baseline to week 26 in AHI4

This document is confidential.

In the previously conducted Phase 2 Mariposa study, the standard deviation of the placebo group change from baseline in AHI4 was approximately 9.0. Based on the observed dropout rates in Mariposa, it is assumed that the dropout rate in the placebo group will be 5% and the dropout rate in the AD109 group will be 25%. For the primary analysis, missing data will be handled under a missing not at random assumption by using multiple imputation from the control group. Based on the assumed standard deviation, anticipated dropout rates and planned method of handling missing data, the required sample size was estimated using simulation. A total of 640 participants (320/group) will provide >98% power to detect a treatment difference of ≥ 4 points between AD109 and Placebo for the change in AHI4.

Change from baseline to week 26 in PROMIS Fatigue T-score

In the Phase 2 Mariposa study, the standard deviation of the placebo group change from baseline in PROMIS Fatigue T-score was 8.6. Based on the observed dropout rates in Mariposa, it is assumed that the dropout rate in the placebo group will be 5% and the dropout rate in the AD109 group will be 25%. For the primary analysis, missing data will be handled under a missing not at random assumption by using multiple imputation from the control group. Based on the assumed standard deviation, anticipated dropout rates and planned method of handling missing data, the required sample size was estimated using simulation. A total of 640 participants (320/group) will provide ~90% power to detect a treatment difference of 2.5 points and ~95% power to detect a treatment difference of 2.75 points.

4.3. Treatment Assignment and Blinding

Participants who meet all eligibility criteria will be randomized 1:1 to either AD109 or placebo, stratified by cohort (Primary cohort, non-GLP-1 use for weight loss vs Exploratory cohort, GLP-1 use for weight loss), baseline AHI4 (<15, 15 to 30, >30) and PROMIS-Fatigue raw score (<25 vs ≥ 25). To ensure representative distribution of enrollment across strata, the size of strata will be controlled through enrollment limits, with AHI4 <15 representing ~20-40% of participants, AHI4 15 to 30 representing ~20-40% of participants, and AHI4 >30 representing ~20-40% of participants.

Randomization will be centralized and will use Interactive Response Technology (IRT). Each participant will be assigned a unique randomization number that encodes the participant's assignment to 1 of the study arms, according to the randomization schedule.

The participants, site personnel, and investigators are masked to the randomized treatment assignment for the entire study duration. Also, the sponsor personnel and all CRO personnel will be masked to treatment assignment until database lock and unblinding has been declared. with

This document is confidential.

the exception of those personnel required to be unblinded for specific reasons (e.g., drug packaging, preparation of unblinded DMC analyses, generation of randomization codes, etc.)

During the study period, unblinding of a participant's study treatment assignment is allowed if determined by the Investigator to be necessary to protect participant safety. The date and reason that the blind was broken must be recorded in the source documentation and electronic case report form (eCRF), as applicable.

Unblinding related to functions of the Data Monitoring Committee (DMC) is described separately in the DMC charter.

At the end of the study, the formal database lock will be declared after the completion of all procedures related to data cleaning, the medical review of the data, agreement of the final participant disposition, and agreement of the analysis populations upon review of all protocol deviations. Once database lock has been declared, the study will be unblinded and the participant's treatment assignments will be added to the clinical database for analysis. The sponsor/sponsor's designee will then be granted access to the unblinded database in order to analyze the data.

This document is confidential.

5. Analysis Sets

5.1. Screened Set

The **Screened Set** will include all participants who signed the informed consent form (ICF), including screen failures.

5.2. Enrolled Set

The **Enrolled Set** will include all participants who signed the ICF and meet all eligibility criteria.

5.3. Primary Full Analysis Set

The **Primary Full Analysis Set (PFAS)** consists of all participants who were randomized into the non-GLP-1 cohort and received at least 1 dose of study drug. All participants enrolled at Site 1416 will be excluded. The PFAS Participants will be used for the primary analysis of the primary and secondary efficacy endpoints, as well as the exploratory endpoints, according to the treatment group into which they are randomized.

5.4. Full Analysis Set

The **Full Analysis Set (FAS)** consists of all participants who were randomized and received at least 1 dose of study drug. All participants enrolled at Site 1416 will be excluded. The FAS may be used for analyses of efficacy endpoints according to the treatment group into which they are randomized.

5.5. Modified Intent to Treat Set

The Modified Intent to Treat (MITT) set for AHI consists of all participants who were randomized into the non-GLP-1 cohort and received at least 1 dose of study drug and had one post baseline PSG assessment. All participants enrolled at Site 1416 will be excluded. The MITT Participants will be used for the supportive analysis of selected efficacy endpoints, according to the treatment group into which they are randomized.

5.6. Safety Set

The **Safety Set (SS)** consists of all participants who are randomized and receive at least 1 dose of investigational medicinal product (IMP). Participants will be analyzed according to treatment received. The SS will be used for all analyses of safety endpoints.

5.7. Per Protocol Set

Per Protocol Set for AHI4 (PPS-A)

This document is confidential.

The Per Protocol Set for AHI4 (PPS-A) consists of all participants in the PFAS, who completed the study treatment up to week 26 (i.e., visit 6) with at least 70% compliance of taking study drug and have non-missing AHI4 assessment at week 26, without any important protocol violations that could influence the efficacy assessments. All participants enrolled at Site 1416 will be excluded. The analyses using the PPS-A will be based upon the actual treatment assignment. Selected efficacy assessment related to AHI4, ODI3 and HB4 will be evaluated using the PPS-A.

The Per Protocol Set for PROMIS-Fatigue (PPS-P)

The Per Protocol Set for PROMIS-Fatigue (PPS-P) is defined in the same way as PPS-A except it requires non-missing PROMIS-Fatigue assessment at baseline and week 26 instead, of AHI4. Selected efficacy assessment related to PROMIS-Fatigue and PROMIS- Sleep Impairment will be evaluated using the PPS-P.

Criteria for exclusion from the PPS-A and PPS-P will be defined in the Protocol deviation and Non-compliance plan and will be determined at the Blinded Data Review Meeting (BDRM) before database lock and unblinding.

This document is confidential.

6. General Aspects for Statistical Analysis

6.1. General Methods

- All analyses and summary outputs will be generated using SAS[®] version 9.4 or higher. All SAS programs used to generate analytical results will be developed and validated according to SYNH programming standards and SAS validation procedures.
- Unless otherwise specified, summaries will be presented for each treatment and overall and visit/time point where applicable.
- Continuous variables will be summarized using the number of observations (n), mean, standard deviation (SD), median, Interquartile range, minimum, and maximum. The minimum and maximum will be displayed to the precision with which the data were collected. The mean, median, and quartiles will be displayed to one additional decimal place and the SD will be displayed to two additional decimal places, where applicable. All CIs will be 2-sided 95% CIs, unless otherwise specified.
- Categorical variables will be summarized using number of observations (n), frequency and percentages of participants in each group and visit/time point where applicable, where the denominator for percentages is the underlying analysis set, unless otherwise stated. All percentages will be presented with one decimal, unless otherwise specified. Percentages equal to 100 will be presented as “100”, and percentages will not be presented for zero frequencies.
- Efficacy data will be listed, tabulated, and summarized graphically, as appropriate. In general, descriptive statistics for efficacy endpoints will be presented using the FAS population. Safety endpoints will be presented using the SS population.
- In general, participant data listings will be presented using the enrolled set.

6.2. Key Definitions

6.2.1. Coding Dictionaries

Adverse events and medical history will be coded into Preferred Term (PT) and System Organ Class (SOC) using the Medical Dictionary for Regulatory Activities (MedDRA) Version 27.0 or higher.

Medications will be coded using the World Health Organization Drug Dictionary (WHO-DD), Global B3 March 2023 or higher.

This document is confidential.

6.2.2. Study Day

The day of first dose of IMP is defined as Study Day 1.

Study day for an event or measurement occurring before the date of the first dose will be calculated as follows:

$$\text{Study Day} = (\text{Event/Measurement Date} - \text{Date of First Dose})$$

Study day for an event or measurement occurring on the date of the first dose is 1. Study day for an event or measurement occurring on or after the date of the first dose to the date of the last dose will be calculated as follows:

$$\text{Study Day} = (\text{Event/Measurement Date} - \text{Date of First Dose}) + 1$$

6.2.3. AHI4 Strata

AHI4 strata is defined as AHI4: <15, 15-<30 and ≥30 derived from AHI4 score at baseline

6.2.4. Randomization Strata

Randomization strata is defined as AHI4: <15, 15-<30 and ≥30 derived from AHI4 score at baseline, and PROMS-Fatigue raw score: <25 vs ≥25 derived from PROMS-Fatigue scores at screening visit 1.

6.2.5. Baseline

In this study, baseline will be defined as the last nonmissing value collected prior to the first IMP administration. This definition will be applied for all analyses. In case of randomized not treated participants, the last nonmissing valid value prior to randomization is used.

6.2.6. Change and Percent Change from Baseline

The change and percent change from baseline will be calculated for each post baseline assessment as:

$$\text{Change} = \text{post baseline value} - \text{baseline value}$$

$$\text{Percent change} = 100 * \text{change} / \text{baseline value}$$

6.2.7. Study Completion

A participant is considered to have completed the study if he/she has completed all phases of the

This document is confidential.

study through the last scheduled procedure shown in the Schedule of Activities (SoA) in the study protocol.

6.2.8. Duration of Treatment

Total treatment duration in days is defined as (last dose date – first dose date + 1), reported to one decimal place, regardless of any temporary interruptions in study drug. If the last study drug dosing date is missing, the latest date among the study drug end date, clinical visit date, laboratory sample collection date, and vital signs assessment date that occurred during the on-treatment period will be used for participants included in the final analyses.

6.2.9. Treatment Emergent AEs (TEAEs)

TEAEs are defined as an AE with an onset (i.e., start date) on or after the first administration of IMP (or any worsening of a pre-existing medical condition on or after the first administration of IMP) and prior to the last date of administration of IMP plus 7 days. Incomplete start dates will be imputed as described in 6.3 **Error! Reference source not found.** and used equivalently.

6.3. Missing Data

Missing data will be maintained as missing unless otherwise specified. For all efficacy variables, methods to handle missing data are described in the analysis of the efficacy variable.

For missing/partial dates with respect to AEs and Medications, the following rules will be followed.

Algorithm for Treatment Emergent Determination of Adverse Events

START DATE	STOP DATE	ACTION
Known	Known	If start date < study medication start date or start date > study medication end date + 7 days, then not TEAE If study medication start date ≤ start date ≤ study medication end date + 7 days, then TEAE
	Partial	Impute stop date as latest possible date (i.e. last day of month if day unknown or 31 st December if day and month are unknown), then: If start date < study med start date or start date > study med end date + 7 days, then not TEAE If study med start date ≤ start date ≤ study med end date + 7 days, then TEAE

This document is confidential.

START DATE	STOP DATE	ACTION
	Missing	If start date < study med start date or start date > study med end date + 7 days, then not TEAE If study med start date ≤ start date ≤ study med end date + 7 days, then TEAE
Partial, but known components show that it cannot be on or after study medication start date or cannot be before study medication end date + 7 days	Known	Not TEAE
	Partial	Not TEAE
	Missing	Not TEAE
Partial, could be on or after study medication start date but before study med end date + 7 days	Known	If stop date < study med start date, then not TEAE If stop date ≥ study med start date, then TEAE
	Partial	Impute stop date as latest possible date (i.e. last day of month if day unknown or 31 st December if day and month are unknown), then: If stop date < study med start date, then not TEAE If stop date ≥ study med start date, then TEAE
	Missing	Assumed TEAE
Missing	Known	If stop date < study med start date, then not TEAE If stop date ≥ study med start date, then TEAE
	Partial	Impute stop date as latest possible date (i.e. last day of month if day unknown or 31 st December if day and month are unknown), then: If stop date < study med start date, then not TEAE If stop date ≥ study med start date, then TEAE
	Missing	Assumed TEAE

This document is confidential.

Algorithm for Prior / Concomitant Medications

START DATE	STOP DATE	ACTION
Known	Known	If stop date < study med start date, assign as prior If stop date $\geq$ study med start date and start date < study med start date, assign as prior concomitant If stop date $\geq$ study med start date and start date $\leq$ end of treatment, assign as concomitant If stop date $\geq$ study med start date and start date > end of treatment, assign as post study
	Partial	Impute stop date as latest possible date (i.e. last day of month if day unknown or 31st December if day and month are unknown), then: If stop date < study med start date, assign as prior If stop date $\geq$ study med start date and start date < study med start date, assign as prior concomitant If stop date $\geq$ study med start date and start date $\leq$ end of treatment, assign as concomitant If stop date $\geq$ study med start date and start date > end of treatment, assign as post study
	Missing	If stop date is missing could never be assumed a prior medication If start date $\leq$ end of treatment, assign as concomitant If start date > end of treatment, assign as post treatment
Partial	Known	Impute start date as earliest possible date (i.e. first day of month if day unknown or 1st January if day and month are unknown), then: If stop date < study med start date, assign as prior If stop date $\geq$ study med start date and start date < study med start date, assign as prior concomitant If stop date $\geq$ study med start date and start date $\leq$ end of treatment, assign as concomitant If stop date $\geq$ study med start date and start date > end of treatment, assign as post study

This document is confidential.

START DATE	STOP DATE	ACTION
	Partial	Impute start date as earliest possible date (i.e. first day of month if day unknown or 1 st January if day and month are unknown) and impute stop date as latest possible date (i.e. last day of month if day unknown or 31 st December if day and month are unknown), then: If stop date < study med start date, assign as prior If stop date ≥ study med start date and start date < study med start date, assign as prior concomitant If stop date ≥ study med start date and start date ≤ end of treatment, assign as concomitant If stop date ≥ study med start date and start date > end of treatment, assign as post study
	Missing	Impute start date as earliest possible date (i.e. first day of month if day unknown or 1 st January if day and month are unknown), then: If stop date is missing could never be assumed a prior medication If start date ≤ end of treatment, assign as concomitant If start date > end of treatment, assign as post treatment
Missing	Known	If stop date < study med start date, assign as prior If stop date ≥ study med start date, assign as concomitant Cannot be assigned as ‘post treatment’
	Partial	Impute stop date as latest possible date (i.e. last day of month if day unknown or 31 st December if day and month are unknown), then: If stop date < study med start date, assign as prior If stop date ≥ study med start date, assign as concomitant Cannot be assigned as ‘post treatment’
	Missing	Assign as concomitant

6.4. Visit Windows

The Screening Period will last up to 4 weeks. Following the Screening Period, all eligible participants will be randomized on Visit 3 (Day 1), and then will be followed by a 1-week low dosing Run-in Period and 25-week target dosing period. The Dose Evaluation Period ends at

This document is confidential.

Visit 6/Week 26. The End of Study visit, visit 7, occurs approximately 2 weeks following cessation of study drug by participants, at Day 194 ± 4 .

The visit windows, defined below in Tables 1a - 1c, will be used to report by visit assessments for efficacy and safety displays. Except in the case of repeated labs, if two or more observations fall within the same visit window, the observation closest to the target day will be used in the analyses. If the observations are equidistant from the target day, the later observation will be used. If labs are repeated and both values fall within the visit window, the result from the repeated lab will be used. Nominal visit information will be displayed in the respective by participant listing.

Table 1a: Analysis Visit Windows for assessment with scheduled visits of week 4 and 26 and week 28

Scheduled Visit*	Target Day	Visit Window (day)
Screening (Visit 1,2,3)	N/A	[-28 to 1]
Visit 4/Week 4	30	[2, 105]
Visit 6/Week 26	180	[106, 187]
Visit 7/EOS Week 28	194	$\geq 188^*$

*No upper limit so all assessments after specified study day will be included for EOS visit.

Table 1b: Analysis Visit Windows for assessment with scheduled visits of week 4 and 26 but not week 28

Scheduled Visit*	Target Day	Visit Window (day)
Screening (Visit 1,2,3)	N/A	[-28 to 1]
Visit 4/Week 4	30	[2, 105]
Visit 6/week 26	180	$\geq 106^*$

*No upper limit so all assessments after specified study day will be included for EOS visit.

Table 1c: Analysis Visit Windows for assessment with schedule visits of week 4, 13, 26 and week 28

Scheduled Visit	Target Day	Visit Window (day)
Screening (Visit 1,2,3)	N/A	[-28 to 1]
Visit 4/Week 4	30	[2, 60]

This document is confidential.

Visit 5/Week 13	90	[61, 135]
Visit 6/week 26	180	≥ 136 (excluding nominal Visit 7/EOS visit)
Visit 7/EOS Week 28	194	Nominal visit 7 as collected

6.5. Pooling of Centers

Data from all sites will be pooled together for all analyses. Funnel plots will be used for the primary endpoint (AHI4) and first three secondary endpoints (PROMIS Fatigue, ODI3, and HB4) to assess the influence of sites on the overall summary measures. Funnel plots will be generated without pooling.

6.6. Outliers

All reported values will be included in the analyses. If any outliers are identified, analyses may be conducted both with and without the outliers. Any outliers will be flagged in the analysis dataset and identified prior to unblinding.

6.7. Sub-groups

The following sub-groups will be used for the analysis of the primary and first secondary endpoint based on the PFAS:

- Age (< 65 vs ≥ 65)
- Gender
- Race (Asian, Black or African American, White, Other)
- Baseline AHI4 (<15 , 15 to <30 , ≥ 30)
- Baseline PROMIS-Fatigue raw score (<25 vs ≥ 25)
- Baseline BMI (<18.5 , 18.5-24.9, 25-29.9, 30-34.9, 35-39.9, ≥ 40 after rounding to 1 decimal place), <18.5 and 18.5-24.9 are combined for the purpose of subgroup analysis.

6.8. Multiplicity

As there is a single primary endpoint, with a single primary hypothesis test, no adjustment for multiplicity is needed for the primary hypothesis test, which will use a two-sided 5% significance level.

This document is confidential.

Adjustment for multiplicity of the key secondary endpoints will be conducted through a closed testing approach, where each key secondary endpoint will be tested in pre-specified order as follows.

1. Change from baseline to week 26 in ODI3
2. Change from baseline to week 26 in PROMIS-Fatigue
3. Change from baseline to week 26 in HB4
4. Change from baseline to week 26 in PROMIS-Sleep Impairment
5. Proportion of patients with $\geq 50\%$ reduction in AHI4 at week 26

If the primary endpoint is statistically significant, then the first key secondary endpoint will be tested using a two-sided 5% significance level. If the first key secondary endpoint is significant, the second key secondary endpoint will be tested using a two-sided 5% significance level, and so on, until an endpoint is found to be not significant (using a two-sided 5% significance level), or all key secondary endpoints have been tested.

No adjustment for multiplicity will be made for the non-key secondary endpoints or exploratory endpoints.

This document is confidential.

7. Demographic, Other Baseline Characteristics and Medication

7.1. Participant Disposition and Withdrawals

All participants who provide informed consent will be accounted for in this study.

The number and percentage of participants screened, screen failed, reason for screen failure, randomized, included and excluded from each analysis set (including reasons for exclusion), completed 26 weeks study drug intake, discontinued study drug prior to week 26 weeks and reasons, discontinued study drug intake prior to week 26 but are observed in the study until week 26, completed the study and or prematurely discontinued the study, including reasons for discontinuation will be summarized for each treatment group and overall.

The duration on study will be summarized for each treatment group and overall.

A listing of participant disposition will also be presented using the enrolled set.

A listing of participant excluded from each analysis set will be presented using the enrolled set.

7.2. Protocol Deviations

A summary of important protocol deviations will be presented by treatment group and overall for the PFAS. A listing of all important deviations will be provided for the enrolled set.

7.3. Demographic and Baseline Characteristics

Demographic and Baseline characteristics will be listed and summarized by treatment group and overall using appropriate descriptive statistics for the PFAS.

The demographic characteristics to be summarized include age (year), sex, race, ethnicity, baseline height (cm), weight (kg), and BMI (kg/m²).

$$\text{BMI (kg/m}^2\text{)} = \text{Weight(kg)} / [\text{Height(m)}^2]$$

Age and BMI will be summarized both continuously and categorically. Age and BMI categories to be used are as follows:

- Age: <65, ≥65
- BMI: <18.5, 18.5-24.9, 25-29.9, 30-34.9, 35-39.9, ≥40

Baseline characteristics include the following:

- Baseline AHI4 score and AHI group: <15, ≥15 to 30, >30 to 50, ≥ 50

This document is confidential.

- Baseline OSA Severity: None=AHl4 <5, Mild=AHl4 5 to <15, Moderate=AHl4 15 to <30, and Severe= AHl4 ≥30.
- Baseline AHl3a
- Baseline ODI3
- Baseline PROMIS-Fatigue raw score, T-score and PROMIS-Fatigue raw score group: <25 vs ≥25
- Baseline PROMIS-Sleep Impairment raw score and T-score
- Baseline PGI-S
- Baseline ESS
- Baseline HB4

7.4. Medical History and Concomitant Diseases

Medical history will be collected, including significant past and current medical conditions, especially autoimmune or inflammatory diseases; surgical history; and disease history, including date of diagnosis, prior treatment(s) and response(s), and notation of any remarkable toxicities. All medical history will be coded using the most recent version of the Medical Dictionary for Regulatory Activities (MedDRA) Version 27.0 or higher

Medical history will be summarized by MedDRA system organ class (SOC) and preferred term (PT) by each treatment group and overall using the PFAS. A participant who experienced more than one medical history within a given SOC and/or PT will be counted only once within that SOC and PT, respectively.

Medical history findings will be listed chronologically by participant for the FAS.

7.5. Medications

7.5.1. Prior/Concomitant Medication

Prior medication is any medication taken prior to the first IMP administration. A concomitant medication is any medication that started or continued after the first IMP administration and on or before the end of study treatment (last dose of IMP).

This document is confidential.

Partial/missing start and/or end dates will be handled as described in the section on missing data (6.3).

All prior and concomitant medication will be classified using the Anatomical Therapeutic Chemical (ATC) classification codes level 4 (ATC 4) and preferred name (PT) (ATC2) from the World Health Organization Drug Dictionary (WHO-DD) Global B3, March 2023.

The prior and concomitant medications will be summarized by treatment group, and overall for the PFAS, using the ATC 4 level term as an upper classification level and the preferred drug name as a lower classification level. All medications will be summarized by descending frequency of ATC level 4 and PT within a given ATC level 4 term. The summary will include the number and percent of the participants who used the medication at least once by treatment group and total using the PFAS.

For each participant, the medication will be counted only once within a level 4 ATC and only once within a given preferred drug name level. A participant may appear more than once if he/she has more than one medication coded under different ATC categories; however, the participant will be counted only once in the overall category.

A by-participant listing with coded terms will also be provided along with calculated study start and stop days for all randomized participants.

7.6. Medical Device Use

A prior device is any device used prior to the first IMP administration. A concomitant device is any device that started or continued to be used after the first IMP administration and on or before the end of study treatment (last dose of IMP).

The prior and concomitant medical device will be classified by System Organ Class (SOC) and Preferred Term (PT) using MedDRA Version 27.0 or higher.

The prior and concomitant medical device use will be summarized by treatment group and overall for the PFAS. The summary will include the number and percent of the participants who used medical device at least once by treatment group. For each participant, the medical device use will be counted only once within each SOC and only once within a given preferred drug name level.

A summary of the number and percentage of participants who discontinued use of a PAP device, in those who were on a PAP device at study initiation will be provided.

This document is confidential.

A summary of the number and percentage of participants who initiated use of a PAP device, in those who were not on a PAP device at study initiation will be provided.

A by-participant listing with coded terms will also be provided along with calculated study start and stop days for the FAS.

7.7. Prior and Concomitant Medical or Surgical Procedure

A medical or surgical procedure is collected with an indication of adverse event, medical history, prophylaxis or other.

A prior procedure is any procedure used prior to the first IMP administration. A concomitant procedure is any procedure that started or continued to be used after the first IMP administration and on or before the end of study treatment (last dose of IMP).

The prior and concomitant procedure will be classified by System Organ Class (SOC) and Preferred Term (PT) using MedDRA Version 27.0 or higher.

The prior and concomitant procedure will be summarized by treatment group and overall for the PFAS. The summary will include the number and percent of the participants who had procedure done at least once by treatment group. For each participant, procedure will be counted only once within each SOC and only once within a given preferred name level.

A by-participant procedure listing with coded terms will also be provided along with calculated study start and stop days for the FAS.

7.8. Extent of Exposure

The treatment duration (days) defined in [Section 6.2.8](#)

The duration of exposure (days) = treatment duration - duration of interruption, where duration of interruption (days) = sum of (interruption end date - interruption start date + 1)

The actual number of doses taken is the sum of quantity dosed across all visits.

The treatment duration, duration of exposure, total number of dose received will be summarized as a continuous variable by treatment group for main cohort of the SS.

A listing of participant drug administration will also be provided for the SS.

7.9. Treatment Compliance

The study drug dispensed, dosed, remaining or missing are recorded by the Interactive Response Technology (IRT) system.

This document is confidential.

The number of doses expected is calculated as:

$$\text{Total number of doses expected (doses)} = \text{Duration of Exposure} * 1 \text{ (dose/day)}$$

The drug compliance is calculated as:

$$\text{Overall treatment compliance} = 100 * (\text{Total number of doses received} / \text{Total number of doses expected})$$

The number and percent of participants with dose interruptions, reason for interruption, overdose, overall treatment compliance, categorical compliance (<50%, 50-<60%, 60%-<70%, 70%-<80% 80-100%, >100-120%, >120%) will be summarized by treatment group, and overall for the PFAS and the SS.

A listing of participant treatment compliance will be provided for the SS.

This document is confidential.

8. Efficacy

All efficacy analyses will be based on the PFAS. Supportive analyses will be based on the MITT set and PP sets.

8.1. Primary Efficacy Estimand(s)/Endpoint(s) and Analysis

The primary efficacy endpoint is the change from baseline to week 26 in AHI4.

The apnea-hypopnea index (AHI) is a diagnostic tool for determining the presence and severity of obstructive sleep apnea (OSA). OSA participants experience a collapse of their airways during sleep. When this causes their breathing to completely stop or reduce to 10% of normal levels for at least 10 seconds, it is called an apnea. Hypopneas occur when the airways partially collapse, resulting in shallow breathing. If the airflow decreases by more than 30% for at least 10 seconds, it can be considered a hypopnea. The AHI represents the average number of apneas and hypopneas participant experienced each hour during sleep. Normal AHI is less than 5 events per hour, while mild AHI is at least five events per hour, but less than 15; moderate AHI is at least 15 events per hour, but less than 30; Severe AHI is equal or more than 30 events per hour. AHI4 is AHI based on 4% hypopnea desaturation and collected at screening, week 4 and 26 visits.

The primary hypothesis:

- H_0 (null hypothesis): $\Delta_{AD109} - \Delta_{Placebo} = 0$,
- H_1 (alternative hypothesis): $\Delta_{AD109} - \Delta_{Placebo} \neq 0$,

where Δ_{AD109} and $\Delta_{Placebo}$ are the corresponding mean change from baseline to week 26 for the AD109 and placebo groups, respectively.

Primary Analysis

The primary analysis methodology will utilize a restricted maximum likelihood (REML) based mixed model for repeated measurements (MMRM) in combination with the Newton Raphson Algorithm. Analyses will include treatment, AHI4 strata, time and the treatment by time interaction as a fixed effects and baseline score as a covariate. An unstructured covariance matrix will be used to model the within participant error. If the model fails to converge with an unstructured covariance matrix, a compound symmetric covariance matrix will be used. In the case that a structured variance-covariance matrix is used to enable the model to converge, the "sandwich" estimator of the variance-covariance matrix will be employed. The Kenward-Roger approximation will be used to estimate the denominator

This document is confidential.

degrees of freedom. The analysis will be implemented using the MIXED procedure in SAS. The lsmeans, and treatment difference in lsmeans for week 4 and 26 will be reported along with the corresponding 95% confidence intervals and the p-values for the treatment group comparisons at week 4 and 26. The primary comparison will be the contrast between treatment groups at week 26.

All data collected up to week 26, regardless of adherence to investigational intervention, and initiation of PAP will be used in the analysis. While every effort will be made to retain participants who discontinue investigational intervention in the trial, it is expected that there will be some missing data for a small proportion of participants at week 26. Based on a previously conducted phase 2 study (Mariposa), we anticipate that up to 5% of placebo participants and 25% of AD109 participants may be missing their week 26 data due to early withdrawal from the trial prior to week 26. Given the anticipated unequal distribution of missing data between the AD109 and Placebo group, missing data will be assumed to be missing not at random (MNAR) and the endpoint will be analyzed using a pattern- mixture model using a control-based approach by means of sequential modelling with multiple imputation as described by [O’Kelly \(2014\)](#).

We distinguish between monotone and non-monotone missing values. Non-monotone missing values are values missing intermittently, where a participant may miss some assessments but has assessments for the same score later in time. Monotone missing values are such that once a value is missing for a given score, no subsequent values for this score are available.

Any given participant may have a combination of non-monotone and monotone missing values.

Non-monotone missing data will be imputed first, followed by the imputation of monotone missing data.

Non-monotone missing values are assumed MAR and will be imputed using a Markov Chain Monte Carlo (MCMC) method of Proc MI in SAS. The imputation model will include the following:

- Treatment arm (active or placebo)
- Baseline AHI4 score
- Baseline PROMIS Fatigue Raw Score
- Age
- BMI

This document is confidential.

To impute monotone missing values, we define patterns depending on reason and timing of missingness as follows:

- **Pattern 1:** missing values before or at week 26 due to participant discontinuation from the study.
- **Pattern 2:** missing values before or at week 26 due to missing/invalid outcome measure.
- **Pattern 3:** missing values before or at week 26 with missingness that does not satisfy conditions of patterns 1 to 2.

The patterns are mutually disjointed, i.e., each participant with monotone missing data belongs only to one pattern.

The following assumptions will be made for the missing data in each pattern:

For **pattern 1**, control-based approach will be used for the active arm. For the placebo arm, multiple imputation under MAR assumption will be used.

For **pattern 2 and 3**, data will be assumed to be MAR in both treatment arms.

The imputation of monotone missing data will be done sequentially for visit, $k=1, 2$ (where 1 corresponds to week 4, and 2 corresponds to week 26) as follows:

- a) For the pattern 1 AD109 participants only, impute the monotone missing values at visit k using the multiple imputation regression model including the effects for baseline covariates as listed for the imputation model of non-monotone missing data above and outcome measure values at each schedule assessment time point up to $(k-1)$; at this step we will include all participants from the active arm with missing data at visit k , plus participants from the placebo arm with visit k data observed. We omit participants from the active arm with outcomes observed at visit k . Multiple imputation will now estimate regression parameters for visit k using data from the placebo arm only. The imputed data for visit k for a participant from the active arm will look like the imputed data for a similar participant from the placebo arm.
- b) For pattern 2, 3 and for pattern 1 placebo participants only, impute the monotone missing values at visit k using an MAR-based multiple imputation regression model (PROC MI option MONOTONE REG) including the effects for baseline covariates as listed for the imputation model of non-monotone missing data above and outcome measure values at each schedule assessment time point up to $(k-1)$.

This document is confidential.

The above steps (a)-(b) are performed for each visit k , before proceeding with the imputations of the next visit ($k+1$).

A total of $M=100$ imputed datasets will be created. The random number generator seed for the imputation of non-monotone missing values using MCMC will be 1717, and the random seed for imputation of monotone missing values will be $1717+k$, for $k=1, 2, \dots$ for each sequential visit with monotone missing data. For monotone missing imputation, the specified seed will be used for the first dataset.

The MMRM modeling with the identical setup as described above will be performed for each imputed dataset.

The SAS MI Analyze procedure will be used to combine the results of these analyses for the imputations by using Rubin's rule.

Supportive Analyses

The following supportive analyses will be performed:

- 1) The analysis of the primary efficacy endpoint of change from baseline in AHI4 at week 26 will be repeated using PFAS and MITT set and a while on treatment estimand approach under Hypothetical Strategy. For this analysis all data collected after a participant has discontinued treatment will be set to missing. This analysis aims at estimating the effect of AD109 compared with placebo in participants with mild to severe OSA who are not taking GLP-1 agonists for weight loss with respect to the change from baseline in AHI4 while on treatment. The same statistical method (i.e., MMRM) will be applied, however missing data will not be imputed and will be assumed to be MAR.
- 2) The analysis of the primary efficacy endpoint will be repeated using the PPS-A set using observed data.

Observed Data Summaries

A descriptive summary of the actual and change from baseline values will be provided for each scheduled visit by treatment group considering only the observed data, i.e., without any imputation for missing values.

Sub-group Analysis

The primary endpoint will also be reported by sub-groups of interest to verify consistency of results across sub-groups. Sub-group analyses will only include participants with known sub-

This document is confidential.

group data and participants missing sub-group information will be excluded. Missing data will be imputed using the same MI approach as described above for the primary analysis. An assessment of consistency will be made by evaluating the lsmeans difference and associated 95% confidence interval of the difference across sub-groups. These estimates will be obtained by fitting the above MMRM model but including fixed effect terms for the sub-group and sub-group by treatment by visit interaction in the model. The lsmeans, and treatment difference in lsmeans for week 4 and week 26 will be reported along with the corresponding 95% confidence intervals for each sub-group. Results will be reported in both tabular format and graphically displayed using Forest plots.

Exploratory Analyses

An exploratory analysis of the primary efficacy endpoint, using the above methods will also be conducted as follows:

- At week 4 for the PFAS, PPS-A and MITT set
- At week 4 and week 26 using the MITT set but on the natural log scale to obtain an estimate of the relative treatment effect. AHI4 will be analyzed on the natural log scale, i.e. $\log(\text{AHI4})$ and the estimated means and LS Means will be back transformed. If AHI4 is reported to be 0, $\log(0.01)$ will be used.

8.2. Key Secondary Efficacy Estimand(s)/Endpoint(s) and Analysis

In this study, the key Secondary Efficacy Endpoints include the following:

- The change from baseline in ODI3 at 26 weeks
- The change from baseline in PROMIS-Fatigue at 26 weeks
- The relative change from baseline in HB4 at 26 weeks (based on natural log scale of HB4)
- The change from baseline in PROMIS-Sleep Impairment T-score at 26 weeks
- Proportion of participants with $\geq 50\%$ reduction in AHI4 at week 26

This document is confidential.

8.2.1. Definition of the Continuous Key Secondary Efficacy Endpoints

In this study, ODI3 and HB4 are assessed at screening, week 4 and 26 visits. PROMIS-Fatigue and PROMIS-Sleep Impairment are assessed at screening, week 4, 13, and 26 visits.

ODI3: Oxygen desaturation index based on 3% hypopnea desaturation measures the frequency of blood oxygen saturation decreases by 3% from baseline per hour of sleep.

HB4: Hypoxic burden based on 4% hypopnea desaturation is a measure to capture the total amount of respiratory event-related hypoxemia over the sleep period. The hypoxic burden was defined as the total area under the respiratory event-related desaturation curve divided by the total area of the sleep duration, with the units of hypoxic burden being (%min)/h. HB4 will be analyzed on the natural log scale of HB4, i.e. $\log(\text{HB4})$ and results will be back transformed. If HB4 is reported to be 0, $\log(0.01)$ will be used in place of $\log(\text{HB4})$.

PROMIS-fatigue and PROMIS-Sleep impairment: PROMIS-Fatigue and Sleep Impairment measures were developed with modern psychometric techniques including item response theory to assess various self-reported aspects of sleep and daytime impairment. Items are based on 5-point scales, either frequency or intensity, with higher scores corresponded to more severe or worse symptoms. The total raw score is the sum of all items.

The total raw scores will be translated into a T-scores with a mean of 50 and a standard deviation (SD) of 10 using scoring tables for PROMIS fatigue and sleep impairment, respectively.

8.2.2. Analyses of the Continuous Key Secondary Efficacy Endpoints

These key secondary endpoints will be analyzed using the PFAS and MITT set.

These key secondary endpoints will be analyzed using the same methods as outlined for the primary endpoint, in Section 8.1, including the supportive, and sub-group analyses as well as the observed summaries.

In addition to an analysis at week 26, these endpoints will also be compared at weeks 4 and 13 (where applicable) as an exploratory analysis using the same analysis methods as applied to week 26.

For PROMIS-Fatigue, and PROMIS-Sleep Impairment, responder analyses of meaningful within participant change (MWPC) will be provided for weeks 4, 13 and 26. Treatment groups will be compared at each post baseline time point using a stratified Cochran-Mantel Haenszel (CMH) test, controlling for randomization strata using the PFAS set. Missing data will not be imputed,

This document is confidential.

and patients with missing data will be imputed as non-responders. The adjusted risk difference of the response rates between AD109 vs placebo, along with the 2- sided 95% CI for the risk difference will be obtained using the Mantel-Haenszel estimate based on the Mantel-Haenszel stratum weights and the Sato variance estimator. The MWPC cut-offs will be defined after DB lock.

Cumulative distribution plots for the change from baseline in PROMIS-Fatigue and PROMIS-Sleep Impairment will be provided for weeks 4, 13 and 26.

8.2.3. Proportion of Participants with $\geq 50\%$ Reduction in AHI4 at Week 26

The proportion of participants with $\geq 50\%$ reduction in AHI4 at week 26 will be compared between treatment groups using the stratified Cochran-Mantel Haenszel procedure, controlling for randomization strata. An estimate of the unadjusted response rates in AD109 and placebo, the adjusted risk difference of the response rates between AD109 vs placebo, along with the 2- sided 95% CI for the risk difference will be presented. The Mantel-Haenszel estimate of the adjusted risk difference, and confidence limits for the adjusted risk difference will be based on the Mantel-Haenszel stratum weights ([Mantel and Haenszel 1959](#)) and the Sato variance estimator ([Sato 1989](#)).

Patients who discontinue study treatment will be considered as non-responders. In the case that there is missing data (i.e., a participant has not discontinued study treatment, but the week 26 PSG was not completed or is not valid), data will be imputed assuming data was missing at random (MAR) using multiple imputation.

We will distinguish between monotone and non-monotone missing values. Non-monotone missing values are values missing intermittently, where a participant may miss some assessments but has assessments for the same score later in time. Monotone missing values are such that once a value is missing for a given score, no subsequent values for this score are available. Any given participant may have a combination of non-monotone and monotone missing values.

Non-monotone missing data will be imputed first, followed by the imputation of monotone missing data.

Non-monotone missing values are assumed to be MAR and will be multiply imputed using a Markov Chain Monte Carlo (MCMC) method of Proc MI in SAS. The imputation model will include the following:

- Treatment arm (active or placebo)

This document is confidential.

- Baseline AHI4 score
- Baseline PROMIS Fatigue Raw Score
- Age
- BMI

The imputation of monotone missing data will be done sequentially for visit, $k=1, 2$ (where 1 corresponds to week 4 and 2 corresponds to week 26) as follows:

- 1) Impute the monotone missing values at visit k using an MAR-based multiple imputation regression model (PROC MI option MONOTONE REG) including the effects for baseline covariates as listed for the imputation model of non-monotone missing data above and observed values at each schedule assessment time point up to $(k-1)$.
- 2) Repeat the above step for each visit k , before proceeding with the imputations of the next visit $(k+1)$.

A total of $M=100$ imputed datasets will be created. The random number generator seed for the imputation of non-monotone missing values using MCMC will be 5879, and the random seed for imputation of monotone missing values will be $5879+k$, for $k=1, 2, \dots$ for each sequential visit with monotone missing data. For monotone missing imputation, the specified seed will be used for the first dataset.

For each imputed dataset, a participant's response will be derived (i.e., $\geq 50\%$ reduction in AHI4) and then each dataset will be analyzed using the stratified CMH test described above.

The individual results will then be combined using Rubin's rule (PROC MIANALYZE). The stratified risk difference is asymptotically normally distributed and can be combined using SAS PROC MIANALYZE directly. To obtain the combined p-value, as the CMH test statistic has a chi-square distribution, it will require transformation to normalize the CMH test statistic. The Wilson-Hilferty transformation will be used to normalize the CMH test statistic.

First, the following transformation will be done:

$$wh_cmh^{(m)} = \sqrt[3]{cmh^{(m)} / df}$$

Where $cmh(m)$ is the CMH statistic computed from the m th imputed dataset, df is the number of degrees of freedom associated with the CMH statistic, and $wh_cmh(m)$ is the transformed value. This transformed statistic is approximately normally distributed with mean $1-2/(9 \times df)$ and variance $2/(9 \times df)$ under the null hypothesis. This value will then be standardized to have a mean of 0 and a variance of 1 as follows:

This document is confidential.

$$St_{wh_cmh(m)} = \frac{\sqrt[3]{cmh(m)/df} - (1 - \frac{2}{(9 * df)})}{\sqrt{\frac{2}{(9 * df)}}}$$

This final transformed variable will then be passed through SAS PROC MIANALYZE to obtain the combined CMH test. The p-value of the combined CMH test is then obtained as the upper tailed p-value from the normal test produced by SAS PROC MIANALYZE on the transformed variable.

Supportive Analyses

The following supportive analyses will be performed:

- 1) The analysis will be repeated using the MITT set and a while on treatment estimand approach. This analysis aims at estimating the effect of AD109 compared with placebo in participants with mild to severe OSA who are not taking GLP-1 agonists for weight loss with respect to achieving a 50% reduction in AHI4 while on treatment. If participants discontinue treatment prior to week 26, their last observation while on treatment will be carried forward (i.e., data from week 4). The same statistical method for analysis of the primary endpoint (i.e., CMH test) will be applied.
- 2) The analysis will be repeated using the PPS-A set .

Sub-group Analyses

The endpoint will also be reported by sub-groups of interest, using the PFAS to verify consistency of results across sub-groups. An assessment of consistency will be made using a stratified CMH test, with sub-group as strata. The risk difference and associated two-sided 95% confidence interval (based on the Wald Method) will be reported for each sub-group. In these analyses, missing data for sub-group inclusion will be maintained as missing, and these participants will not be included. Patients who discontinue study treatment will be considered as non-responders as indicated above. Missing responses (i.e., a participant has not discontinued study treatment, but the week 26 PSG was not completed or is not valid) will be imputed using the same MI approach as described above. Results will be reported in both tabular format and graphically displayed using Forest plots. The p-value from the Breslow-Day test of homogeneity will also be reported. As Breslow-Day test statistic has a chi-square distribution, similar approach as for CMH test will be used to calculate p-values based on MI data.

This document is confidential.

Exploratory Analyses

An exploratory analysis of the proportion of participants with $\geq 50\%$ reduction in AHI4 at week 4, using the above methods will also be conducted using the PFAS, MITT and PPS-A sets.

8.3. Other Secondary Efficacy Endpoints and Analyses

In this study, the other Secondary Efficacy Endpoints include the following:

- The change from baseline in PGI-S for Fatigue at 26 weeks
- PGI-C for Fatigue at 26 weeks
- The change from baseline in ESS at 26 weeks

These endpoints will be analyzed using the PFAS and MITT.

8.3.1. Definition of the Secondary Efficacy Endpoints

PGI-S for Fatigue and ESS are assessed at screening, week 4, 13, and 26 visits. PGI-C is assessed at week 4, 13, and 26 visits.

PGI-S for Fatigue: PGI-S is a single-item scale of the patient's global, i.e., overall impression of severity of fatigue in the past 7 days. The response includes:

- None
- Mild
- Moderate
- Severe
- Very severe

For scoring PGI-S, set none=1, mild=2, moderate=3, severe=4 and very severe=5.

PGI-C for Fatigue: PGI-C for Fatigue is single-item scales of change in the severity of fatigue from pre-treatment to the time point measured. The response includes:

- Much better
- A little better

This document is confidential.

- No change
- A little worse
- Much worse

For scoring PGI-C, set much better=1, a little better=2, no change=3, a little worse=4 and much worse=5.

ESS score: The ESS is a self-administered questionnaire with 8 questions. Participants are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in 8 different activities in recent times. The ESS score (the sum of 8 item scores) can range from 0 to 24. The higher the ESS score, the higher that person's average sleep propensity in daily life, or their 'daytime sleepiness'.

8.3.2. Analyses of the Secondary Efficacy Endpoints

These endpoints will be analyzed using the PFAS and MITT set.

These secondary endpoints will be analyzed using the same methods as outlined for the primary endpoint, in Section 8.1, including the supportive analyses using the MITT set, and sub-group analyses as well as the observed summaries.

For the endpoint PGI-C, as no baseline score is collected for PGI-C the baseline score for PGI-S will be included in the model.

In addition to an analysis at week 26, these endpoints will also be compared at weeks 4 and 13 as an exploratory analysis using the same analysis methods as applied to week 26.

8.4. Exploratory Efficacy Endpoints and Analyses

These endpoints will be analyzed using the PFAS and/or MITT analysis set for AHI as specified.

Percent of participants with AHI4<15, <10 and <5 at 4 and 26 weeks

Treatment groups will be compared at each post baseline timepoint using a stratified Cochran-Mantel Haenszel (CMH) test, controlling for randomization strata. An estimate of the unadjusted response rates in AD109 and placebo, the adjusted risk difference of the response rates between AD109 vs placebo, along with the 2- sided 95% CI for the risk difference will be presented. The Mantel-Haenszel estimate of the adjusted risk difference, confidence limits, and test for the adjusted risk difference will be based on the Mantel-Haenszel stratum weights and the Sato

This document is confidential.

variance estimator. Missing data will be imputed using Last Observation Carried Forward (LOCF) approach.

Cumulative distribution plots of the change from baseline by treatment group will also be produced for weeks 4 and 26 for all participants.

Proportion of participants with AHI4 reduction of $\geq 30\%$ to $\geq 90\%$, by 10%

Treatment groups will be compared at each post baseline time point using a stratified Cochran-Mantel Haenszel (CMH) test, controlling for randomization strata using the PFAS and MITT set respectively. For PFAS, patients with missing data for any reason will be treated as a non-responder, and for MITT, LOCF will be used for missing data for any reason. The adjusted risk difference of the response rates between AD109 vs placebo, along with the 2-sided 95% CI for the risk difference will be produced using the Mantel-Haenszel estimate based on the Mantel-Haenszel stratum weights and the Sato variance estimator.

Change from baseline in AHI3a at 4 and 26 weeks

Change from baseline AHI3a will be analyzed using the same methods as outlined for the primary endpoint, in Section 8.1, including the supportive, and sub-group analyses as well as the observed summaries.

Change from baseline in HB3a and ODI4 at 4 and 26 weeks

These endpoints will be analysed using the MITT set. Treatment groups will be compared at each post baseline time point utilizing a restricted maximum likelihood (REML) based mixed model for repeated measurements (MMRM) in combination with the Newton Raphson Algorithm. Analyses will include treatment, AHI4 strata, time and the treatment by time interaction as a fixed effects and baseline score as a covariate. An unstructured covariance matrix will be used to model the within participant error. If the model fails to converge with an unstructured covariance matrix a compound symmetric covariance matrix will be used. In the case that a structured variance-covariance matrix is used to enable the model to converge, the "sandwich" estimator of the variance-covariance matrix will be employed. The Kenward-Roger approximation will be used to estimate the denominator degrees of freedom. The analysis will be implemented using the MIXED procedure in SAS. The lsmeans, and treatment difference in lsmeans for week 4 and week 26 will be reported along with the corresponding 95% confidence intervals and the p-values for the treatment group comparisons at weeks 4 and 26. Missing data will be assumed to be MAR and maintained as missing.

This document is confidential.

For HB3a, data will be analyzed on the natural log scale of HB3a and results will be back transformed. If HB3a is reported to be 0, $\log(0.01)$ will be used in place of $\log(\text{HB3a})$.

Change from Baseline in Non-Rapid Eye Movement Apnea-Hypopnea Index [NREM AHI] at 4 and 26 weeks

These endpoints will be analysed using the MITT set. Treatment groups will be compared at each post baseline time point utilizing a restricted maximum likelihood (REML) based mixed model for repeated measurements (MMRM) in combination with the Newton Raphson Algorithm. Analyses will include treatment, AHI4 strata, time and the treatment by time interaction as a fixed effects and baseline score as a covariate. An unstructured covariance matrix will be used to model the within participant error. If the model fails to converge with an unstructured covariance matrix a compound symmetric covariance matrix will be used. In the case that a structured variance-covariance matrix is used to enable the model to converge, the "sandwich" estimator of the variance-covariance matrix will be employed. The Kenward-Roger approximation will be used to estimate the denominator degrees of freedom. The analysis will be implemented using the MIXED procedure in SAS. The lsmeans, and treatment difference in lsmeans for week 4 and week 26 will be reported along with the corresponding 95% confidence intervals and the p-values for the treatment group comparisons at weeks 4 and 26. Missing data will be assumed to be MAR and maintained as missing.

Change from Baseline in Rapid Eye Movement Apnea-Hypopnea Index [REM AHI] at 4 and 26 weeks (excluding participants whose PSG has <10 minutes of REM sleep)

These endpoints will be analysed using the MITT set. Treatment groups will be compared at each post baseline timepoint utilizing a restricted maximum likelihood (REML) based mixed model for repeated measurements (MMRM) in combination with the Newton Raphson Algorithm. Analyses will include treatment, AHI4 strata, time and the treatment by time interaction as a fixed effects and baseline score as a covariate. An unstructured covariance matrix will be used to model the within participant error. If the model fails to converge with an unstructured covariance matrix a compound symmetric covariance matrix will be used. In the case that a structured variance-covariance matrix is used to enable the model to converge, the "sandwich" estimator of the variance-covariance matrix will be employed. The Kenward-Roger approximation will be used to estimate the denominator degrees of freedom. The analysis will be implemented using the MIXED procedure in SAS. The lsmeans, and treatment difference in lsmeans for week 4 and week 26 will be reported along with the corresponding 95% confidence intervals and the p-values for the treatment group comparisons at weeks 4 and 26. Missing data will be assumed to be MAR and maintained as missing.

This document is confidential.

Change from baseline in supine AHI4 [AHI4S] at 4 and 26 weeks (excluding participants whose PSG has <10 minutes of supine sleep)

These endpoints will be analysed using the MITT set. Treatment groups will be compared at each post baseline timepoint utilizing a restricted maximum likelihood (REML) based mixed model for repeated measurements (MMRM) in combination with the Newton Raphson Algorithm. Analyses will include treatment, AHI4 strata, time and the treatment by time interaction as a fixed effects and baseline score as a covariate. An unstructured covariance matrix will be used to model the within participant error. If the model fails to converge with an unstructured covariance matrix a compound symmetric covariance matrix will be used. In the case that a structured variance-covariance matrix is used to enable the model to converge, the "sandwich" estimator of the variance-covariance matrix will be employed. The Kenward-Roger approximation will be used to estimate the denominator degrees of freedom. The analysis will be implemented using the MIXED procedure in SAS. The lsmeans, and treatment difference in lsmeans for week 4 and week 26 will be reported along with the corresponding 95% confidence intervals and the p-values for the treatment group comparisons at weeks 4 and 26. Missing data will be assumed to be MAR and maintained as missing.

Change from baseline in: TST and percentage of TST in sleep stages (sleep efficiency [SE]; wake after sleep onset [WASO]; sleep onset latency [SOL]; Stage N1% [N1P], Stage N2% [N2P], Stage N3% [N3P], Stage R% [RP])

These endpoints will be analysed using the MITT set. Descriptive summary, including n, mean, median, SD, minimum and maximum of the observed actual and change from baseline values will be provided for SE, WASO, SOL, N1P, N2P, NP and RP at each scheduled visit by treatment group.

Change from baseline in: Arousal Indices (Arousal Index - Respiratory [ARIR]; Arousal Index - total [ARI])

These endpoints will be analysed using the MITT set. Descriptive summary, including n, mean, median, SD, minimum and maximum of the observed actual and change from baseline values will be provided for ARIR and ARI at each scheduled visit by treatment group.

Change from baseline to week 4 and week 26 in OSA Severity (Mild, Moderate, Severe)

These endpoints will be analysed using the PFAS and MITT set. A shift table showing the change from baseline to week 4 and week 26 in OSA severity will be provided. At baseline, week 4 and week 26 participants will be categorized as either None, Mild, Moderate or Severe,

This document is confidential.

based on their AHI4 score. If a participant is missing AHI4 score, they will be categorized as missing. The following definitions will be used for OSA severity: 1-None: AHI4 <5, 2-Mild: AHI4 5 to <15, 3-Moderate: AHI4 15 to <30, and 4-Severe: AHI4 $\geq$ 30.

Treatment comparing for OSA severity will be performed using CMH (with Modified Riddit Scores) controlling for randomization strata. Coded OSA Severity score 1-4 will be used for this testing and p-value will be reported. Missing data will be excluded.

Exploratory Analysis of Snoring

To examine the effect of AD109 on reducing the degree of snoring, exploratory analyses will be conducted to compare the proportion of loud breaths (i.e., snoring) recorded during the PSG assessment between treatment groups at week 26 using the MITT population. Data from study APC-APN-304 and APC-APN-305 will be combined for this analysis. Results from this analysis will be reported separately from the CSR, and data will not be included in the SDTM and ADaM datasets.

The sound level (i.e., the decibel increase above background noise) and the percentage of breaths recorded above a given sound level, will be used to select participants who are considered to snore at baseline. Given the absence of a standardized definition for snoring in participants, we will employ nine distinct criteria to identify moderate-to-loud snorers using baseline data from the MITT population.

- 1) $\geq$ 5% of breaths with >20 decibel increase from background
- 2) $\geq$ 10% of breaths with >20 decibel increase from background
- 3) $\geq$ 15% of breaths with >20 decibel increase from background
- 4) $\geq$ 5% of breaths with >25 decibel increase from background
- 5) $\geq$ 10% of breaths with >25 decibel increase from background
- 6) $\geq$ 15% of breaths with >25 decibel increase from background
- 7) $\geq$ 5% of breaths with >30 decibel increase from background
- 8) $\geq$ 10% of breaths with >30 decibel increase from background
- 9) $\geq$ 15% of breaths with >30 decibel increase from background

This document is confidential.

For each of these 9 cohorts the percentage of breaths above the decibel threshold used to select the cohort will be summarized at each post baseline time point using descriptive statistics. Treatment groups will be compared at Month 6 using an ANCOVA model that will include treatment, PROMIS Fatigue strata, AHI4 strata, and study as fixed effects and baseline score as a covariate. The lsmeans, and treatment difference in lsmeans will be reported along with the corresponding 95% confidence interval and the p-values for the treatment group comparison. Missing data will be assumed to be MAR and maintained as missing.

This document is confidential.

9. Safety

The population used for all safety analyses will be the Safety Set (SS). Safety will be assessed based on adverse event (AE), clinical laboratory data, ECG parameters, physical examinations, and vital signs. Safety data will be presented by treatment for all participants.

9.1. Adverse Events / Adverse Drug Reactions

All AEs will be coded and classified by System Organ Class (SOC) and Preferred Term (PT) using MedDRA Version 27.0 or higher. All AEs that occur after the first dose of study drug (i.e., date of onset is on or after the first dose of study drug) and on or before the end of treatment (last dose of blinded IMP) + 7 days will be considered treatment emergent adverse events (TEAEs) for the purpose of reporting and will be summarized using frequency counts and percentages. In addition, the number of events will also be provided. Summaries will be presented by treatment group, for the main cohort, and overall. All AEs will be provided in a data listing with an indication of if they are TEAEs. See Section 6.3 for determining if an AE is a TEAE based on partial/missing dates.

Summaries of TEAEs will be presented using the MedDRA level hierarchy (system organ class and preferred term) as follows:

- Overall (i.e., regardless of intensity or relationship to treatment)
- Most common (i.e., regardless of intensity or relationship to treatment) based on a frequency of $\geq 5\%$ in the AD109 group and greater than placebo
- By intensity grade (mild, moderate, severe)
- By relationship to study medication (related, not-related)

Unless otherwise specified, at each level of participant summarization in reporting the incidence of the AEs, a participant will be counted once if the participant reported one or more events. If more than one occurrence of an event is reported, the event of the worst intensity will be summarized. The summaries will be presented by descending frequency by SOC and PT in the overall column and then alphabetically within PT

TEAEs leading to premature discontinuation of study drug and serious TEAEs (SAEs) will also be summarized by treatment group, and relationship. TEAEs leading to premature discontinuation of study drug will be defined as any TEAEs with an action taken regarding study medication equal to “permanently discontinued.”

The following adverse events of special interest (AESIs) have been pre-defined:

This document is confidential.

- Urinary Hesitation
- Urinary Retention
- Liver Injury
 - Hepatic Failure
 - Hepatic Injury
- Cardiovascular
 - Hypotension Group
 - Palpitations Group
 - Myocardial Ischemia
 - Systemic Hypertension
 - Stroke and Transient Ischemic Attack (TIA)
- Suicidal Ideation
- Daytime Sleepiness
- Motor Vehicle Accidents
- Anticholinergic Effects
- Psychiatric disorders
 - Mania
 - Psychosis

Appendix 1 includes the list of FDA Medical Queries (FMQs) and/or consolidated PTs that will be used to identify the above AESIs. The checkbox on the AE eCRF will not be used to identify AESIs.

In addition, an overall summary table will be provided that includes the following:

- Any TEAE
- Any related TEAE
- Any severe TEAE
- Any AESI
- Any TEAE Leading to study drug discontinuation
- Any SAE

9.2. Laboratory Evaluations

In this study, serum and urine samples will be collected for hematology, clinical Chemistry and urinalysis, as described in **Table 2**, at screening visit, Week 4 and 26 visits. The laboratory samples will be analyzed at a central laboratory facility and results will be transferred to the sponsor for data analysis.

This document is confidential.

Table 2: Protocol-Required Safety Laboratory Assessments

Laboratory Assessments	Parameters		
Hematology	Hematocrit Hemoglobin Platelet Count	RBC Count RBC Indices	WBC count with Differential
Serum Chemistry	Albumin BUN Creatinine Potassium Sodium Bilirubin HbA1c	ALT AST Alkaline phosphatase Calcium Magnesium Total Protein	Glucose Total cholesterol HDL cholesterol LDL cholesterol Chloride Bicarbonate Uric acid
Routine Urinalysis	Specific gravity, bilirubin, color, appearance, leukocyte esterase, nitrite, pH, protein (albumin), glucose, ketones, occult blood, urobilinogen Microscopic examination (if positive protein, leukocyte esterase, blood or nitrite)		
Other Tests	• Serum hCG pregnancy test at screening. Additional testing may be performed if needed in WOCBP. • Urine test of drugs of abuse (marijuana, cocaine, amphetamine, methamphetamine, opiates, phencyclidine, barbiturates, benzodiazepines, propoxyphene); immunoassay with gas chromatography-mass spectrometry confirmation of positive results • FSH may be performed to aid in determination of menopausal status		

Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; BUN = blood urea nitrogen; FSH = follicle stimulating hormone; HbA1c = hemoglobin A1c (glycated hemoglobin); hCG = human chorionic gonadotropin; RBC = red blood cell count; WBC= white blood cell; WOCBP = women of childbearing potential.

Results from the hematology, serum chemistry, urinalysis will be summarized for each visit by treatment group and overall using the SS. Summaries will include the observed values and change from baseline values for numeric parameters (number of participants, mean, standard deviation, median, minimum, and maximum) and distribution of categories for categorical parameters (number and percentages).

In addition, shift tables with the categorization of low/normal/high based on the normal range will be provided showing the shift from baseline to each post baseline visit.

This document is confidential.

By participant hematology, serum chemistry, and urinalysis results listings will be generated and flagged as abnormally high or low relative to the reference range, where applicable.

Note:

1. All laboratory results will be summarized in tables and listings using SI units, with select labs using conventional units.
2. Laboratory reference ranges will be used to identify abnormalities with low, normal, or high values.
3. In the summary tables, missing lab results will not be imputed and will be maintained as missing in all descriptive summary statistics.
4. Analysis visit will be used in the summary tables. For each participant, a single result will be selected for each visit.
5. Laboratory tests will be listed in alphabetical order within their respective panels and categories. For example, all liver function tests will be presented together.

9.3. Vital Signs

In this study, the vital signs will be measured at clinic visit and recorded on eCRF at the Screening/Baseline visits (V1, V2 and V3), Week 4, 13, and 26, as outlined in the Schedule of Assessments in study Protocol Table 1. At baseline (V2), Week 4 and Week 26, vital signs will be measured in the evening prior to the PSG and in the morning after the PSG. The Vital signs will include (systolic and diastolic blood pressure (mmHg), Heart Rate (bpm), Body Temperature (C), Respiratory Rate (breaths per minute), height (cm), body weight (kg) and BMI. The systolic and diastolic blood pressure will be measured in seated position after 5 minutes' rest and 3 readings will be collected at each visit. For each timepoint, the average of the last 2 readings will be used for analysis if there are multiple readings.

Vital sign data will be summarized for each nominal visit by treatment group and overall using the SS. Summaries will include the observed values and change from baseline values for numeric parameters (number of participants, mean, standard deviation, median, minimum, and maximum).

Vital sign data will be listed chronologically by participant and visit for each vital sign parameter.

Note:

This document is confidential.

1. In the summary tables, missing vital sign results will not be imputed and will not be counted in the descriptive summary statistics.
2. Nominal visit as collected will be used in the summary tables, i.e. visit window is not applicable. The nominal visits are:
 - Baseline – Day 1 (Evening before PSG)
 - Baseline – Day 2 (Morning after PSG)
 - Baseline – Visit 3
 - Week 4 – Day 1
 - Week 4 – Day 2 (Post PSG)
 - Week 13
 - Week 26 – Day 1
 - Week 26 – Day 2 (Post PSG)
 - EOS Week 28

The following table shows the baseline value to use in deriving the change from baseline for each post baseline nominal visit

Post Baseline Visit	Baseline Value for deriving Change
Week 4-Day 1 Week 26-Day 1	Baseline – Day 1 (Evening before PSG)
Week 4-Day 2 (Post PSG) Week 26-Day 2 (Post PSG)	Baseline – Day 2 (Morning after PSG)
Week 13 EOS Week 28	Baseline – Visit 3 (V3)

9.4. ECG

In this study, a standard 12-lead ECG will be performed locally at the site at the Screening visit, week 26, and End of Study visit as outlined in the Schedule of Assessments in study Protocol Table 1, using an ECG machine that automatically calculates the heart rate (beats/min) and measures PR interval (msec), QRS duration (msec), QT interval (msec), QTcF interval (msec). In addition, the overall ECG interpretation (normal, abnormal CG, abnormal NCG, unable to evaluate) will be assessed.

ECG data will be summarized for each visit by treatment group and overall using the SS. Nominal visit as collected will be used for summaries including baseline, week 26 and end of study. Summaries will include the observed values and change from baseline values for heart

This document is confidential.

rate, PR, QRS, QT, QTcF (number of participants, mean, standard deviation, median, minimum, and maximum) and distribution of overall ECG interpretation (number and percentages).

Additionally, the numbers and percentages of participants with ECG abnormalities at each visit will be presented. The parameters and abnormality criteria are specified in the table below.

Parameter	Abnormality Criterion
PR interval	<110 msec
	>300 msec
QRS interval	≥120 msec
QTcF	<350 msec
	>450msec
	>500msec
	>550msec
Δ QTcF*	>30msec
	>60msec
Heart rate	<50 bpm
	>110 bpm

* Change from baseline in QTcF.

Shift tables will also be used to show the changes from baseline to each post baseline time point based on the above abnormality criteria (with the exception of Δ QTcF).

ECG data will be listed chronologically by participant and visit for each parameter: heart rate, PR, QRS, QT, QTcF and overall ECG interpretation.

Note:

1. In the summary tables, missing ECG results will not be imputed and will not be counted in the descriptive summary statistics.
2. Nominal visit will be used in the summary tables. For each participant, a single result will be selected for each visit. If multiple results available for same visit, the one closest to the target visit day will be selected. If more than one results for same day, the first one will be selected.

9.5. Physical Examination

In this study, a full comprehensive physical examination will be performed at the Screening Visit, which includes the assessment for the following body systems: general Appearance,

This document is confidential.

dermatologic, Head, Eyes, Ears, Nose, Mouth/Throat/Neck, Thyroid, Lymph Nodes, Respiratory, Cardiovascular, Gastrointestinal, Extremities, Musculoskeletal, Neurologic, Psychiatric, Other.

Participants with abnormal physical examination will be summarized by treatment group and overall using the SS, including number and percentage of participant with abnormal physical examination in organ or body system.

Physical examination data will be listed by participant and body system.

9.6. Other Safety

The other safety endpoints include the following:

- Digit Symbol Substitution Test (DSST)
- Psychomotor Vigilance Test (PVT)
- Verbal learning task (VLT)
- Modified cocaine selective severity assessment (M-CSSA)
- Self-reported Montgomery-Asberg depression rating scale (MADRS-S)
- Spielberger Anxiety Inventory (STAI) - short form

DSST: The DSST measures a range of cognitive and motor operations including motor speed, attention, visuo-perceptual functions, and some aspects of associative learning. In this study, the DSST is used as a safety measure for psychomotor impairment related to residual next-day effects of study drug dosed at bedtime. The DSST is a key of nine digit-symbol pairs and a test set of ten digits with empty spaces below them. The individual is instructed to match each digit to its corresponding symbol. When all ten digits of the test set have been matched, a new test set is presented. Individuals are instructed to complete as many digit-symbol matches as possible within 60 seconds. The score is the number of correct symbols filled in within the time limit. Higher scores indicate better performance. Errors are typically not penalized directly, but they do reduce the total number of correct items completed, affecting the overall score. In addition to the number of slots correct, the accuracy rate (defined as the number of matches correct divided by the total number of matches; correct, incorrect and skips) will be reported.

This document is confidential.

PVT: The PVT measures sustained attention and reaction time. In addition to reaction time, the test records lapses, in which the screen is not pressed in response to a cue, and false-positives in which the screen is pressed prior to appearance of the cue. The following endpoints will be derived:

- Accuracy Rate is the percentage of correct responses of all responses (correct or incorrect)
- Mean and Median Correct Response Time (ms)
- No Response Rate is the percentage of no responses
- False Response Rate is the percentage of early responses
- Count of Lapses is the number of no responses or responses with reaction time > 500 ms
- PVT Performance is the percent of correct responses with reaction time ≤ 500 ms out of all correct and incorrect responses.

VLT: The VLT measures the ability to store words in working memory and long-term memory.

The test has two phases, the learning phase (working memory) and the recall phase (long term memory). In the learning phase, participants are instructed to pay attention to a list of 12 spoken words that are visually presented simultaneously on the screen, and to verbally repeat as many words as they can remember from the list. This cycle of presenting and repeating the same words is repeated three times. The recall phase is done after a prescribed delay and divided into the free recall task and the recognition task. During the free recall task, participants are asked to verbally recall as many of the words as they can remember from the original list of words presented during the learning phase. During the subsequent recognition task, participants are sequentially presented with 24 words, which consist of words from the original list and new words (distractors), and are then instructed to respond as to whether that word was one they had heard before or not. There is no single overall summary score. The following domain scores will be provided:

- VLT Learning
 - Immediate Recall in the 1st Trial
 - Immediate Recall 1: number of correct words for first reading of word list
 - Immediate Recall in the 3rd Trial
 - Immediate Recall 3: number correct words for last reading of word list

This document is confidential.

- Learning Rate, defined as the number of correct words in the 3rd trial minus the number of correct words in the 1st trial) / (number of trials -1)
- VLT-Recall
 - Delayed Recall
 - Delayed Recall: number of correct words during the free recall phase (only first row for given block will have this value)
 - Recognition Accuracy
 - Recognition Accuracy: average accuracy value for all recognition trials (all rows except for first row for a given block). This is the proportion of target words and distractor words that were correctly identified.

M-CSSA: the CSSA was originally designed to measure the signs and symptoms of cocaine withdrawal. In this study, a modified version of CSSA is used as a safety measure for withdrawal symptoms that might be caused by AD109, particularly the atomoxetine component, which affects the norepinephrine system, a system also affected by cocaine. The following 17 symptoms are assessed: hyperphagia, hypophagia, carbohydrate craving, study drug craving, study drug craving frequency, sleeping less, sleeping more, anxiety, energy level, activity level, tension, attention, paranoid ideation, anhedonia, depression, suicidality, irritability. Each item of the M-CSSA is scored on a 0-7 Likert scale. A higher score indicates greater severity of each symptom. Summaries will be provided by symptom.

MADRS-S: the Montgomery Asberg Depression Rating Scale – Self Assessment (MADRS-S) is a 9-item diagnostic questionnaire used to measure the severity of depressive symptoms. The following symptoms are assessed; mood, feelings of unease, sleep, appetite, ability to concentrate, initiative, emotional involvement, pessimism and zest for life. Each item is based on a 6-point scale (scored 0, 0.5, 1, 1.5, 2, 2.5, 3), with the overall score ranging from 0-27. Higher scores indicate more severe depression. Question 9 (zest for life) of the MADRS-S deals with suicidality and will be also be reported separately.

STAI: the STAI is a self-completed questionnaire that aims to assess separately state anxiety (a temporary state influenced by the current situation where the respondent notes how participant feels right now at this moment) and trait anxiety (a general propensity to be anxious where the respondent. The STAI short form is scored by summing responses to 6 items (each scored on a 4-point Likert Scale from 1 to 4), yielding scores that reflect the level of anxiety experienced in the moment. The 6 items scored relate to feeling: calm, tense, upset, relaxed, content and worried.

This document is confidential.

To calculate the total STAI score (which ranges from 20-80) based on the STAI short form the following steps are taken:

- 1) reverse score the positive items: calm, relaxed and content are reverse scored (i.e., 1=4, 2=3, 3=2 and 4=1)
- 2) sum all six scores
- 3) multiply the total score by 20/6 to get the total score, with higher scores representing greater anxiety.

The above safety endpoints will be summarized for each visit by treatment group, and overall using the SS. The summaries will include the appropriate descriptive statistics based on the endpoint. For count data, counts and percentages will be provided. For continuous data the absolute value and the change from baseline values will be summarized.

By participant list for DSST, PVT, VLT, M-CSSA, MADRS-A and STAI will be generated, including visit, data/time, itemized response and overall score, where applicable

This document is confidential.

10. Interim Analyses

No interim analysis is planned.

This document is confidential.

11. Changes from Analysis Planned in Protocol

Additional analyses for AHI3a has been added in the same way as AHI4.

The following endpoints are added to the 8.4, Exploratory Efficacy Endpoints and Analyses, which are not included in the protocol.

- Percent of participants with AHI4<15, <10 and <5 at 4 and 26 weeks.
- Proportion of participants with AHI4 reduction of $\geq 30\%$ to $\geq 90\%$ by 10% increments
- Change from baseline in AHI4, AHI3a, HB3a and ODI4 at 4 and 26 weeks (where applicable).
- Non-Rapid Eye Movement Apnea-Hypopnea Index [NREM AHI] at 4 and 26 weeks.
- Rapid Eye Movement Apnea-Hypopnea Index [REM AHI] at 4 and 26 weeks (excluding participants whose PSG has <10 minutes of REM sleep).
- Change from baseline in supine AHI4 [AHIS] at 4 and 26 weeks (excluding participants whose PSG has <10 minutes of supine sleep).
- TST and percentage of TST in sleep stages (sleep efficiency [SE]; wake after sleep onset [WASO]; sleep onset latency [SOL]; Stage N1% [N1P], Stage N2% [N2P], Stage N3% [N3P], Stage R% [RP]).
- Arousal Indices (Arousal Index - Respiratory [ARIR]; Arousal Index - total [ARI]).
- Proportion of participants with $\geq 50\%$ reduction in AHI4 at 4 and 26 weeks.
- Change from baseline to 26 weeks in OSA severity category (None, Mild, Moderate and Severe).
- Proportion of patients with a reduction in loud breaths (i.e., Snoring)

The following endpoints have been removed due to redundancy.

- Proportion of participants with $\geq 50\%$ reduction at 4 and 26 weeks for AHI3a, ODI3.

This document is confidential.

12. Reference List

- O’Kelly, M and Ratitch, B. 2014. *Clinical Trial with Missing Data a Guide for Practitioners* (1st ed.). John Wiley & Sons <https://doi.org/10.1002/9781118762516>
- Mantel, N., and Haenszel, W. (1959). “Statistical Aspects of Analysis of Data from Retrospective Studies of Disease.” *Journal of the National Cancer Institute* 22:719–748.
- Sato, T. (1989). “On the Variance Estimator of the Mantel-Haenszel Risk Difference.” *Biometrics* 45:1323–1324. Letter to the editor.

This document is confidential.

13. Programming Considerations

Programming considerations are presented in TFL shell document.

This document is confidential.

14. Quality Control

SAS programs are developed to produce output such as analysis data sets, summary tables, data listings, figures or statistical analyses. An overview of the development of programs is detailed in Syneos Health Developing Statistical Programs SOP (3920).

Syneos Health End-to-End Process of the Production of Study Data Tabulation Model (SDTM) (3921) and End-to-End Process of Analysis Datasets (ADs) and Tables, Figures and Listings (TFLs) SOPs (3922) and the SAS Programming and Validation Plan describes the quality control procedures that are performed for all SAS programs and output. Quality control is defined here as the operational techniques and activities undertaken to verify that the SAS programs produce the output by checking for their logic, efficiency and commenting and by review of the produced output.

This document is confidential.

15. Example SAS Code for the Primary and Key Secondary Endpoint Analyses

15.1. Imputation Procedures

The sample codes are for numerical endpoint PROMIS-Fatigue that is assessed at week 4 (M1), 13 (M3) and 26 (M6). Similar sample codes can be applied to primary endpoint AHI4 that is collected at week 4 and 26 by using 2 visits.

15.1.1. Non-monotone missing imputation

```
proc mi data=xxx1 seed=1717 nimpute=100 out=xxx2;  
  by TRTP;  
  mcmc impute=monotone;  
  var AHIBL PRFATBL AGE BMIBL M1 M3 M6;  
run;
```

TRTP=Treatment arm (active or placebo), AHIBL= Baseline AHI score, PRFATBL Baseline PROMIS Fatigue Raw Score, AGE=Age, BMI = Body Mass Index, M1/M3/M6 = AHI4 at Week 4/13/26, respectively.

15.1.2. Monotone Missing imputation

Step 1: Impute missing value for M1

AD109 Pattern 1 (dataset xxx2a): Keep all AD109 participants with missing M1 with pattern 1 and all Placebo participants with non-missing M1

```
proc mi data=xxx2a seed=1718 nimpute=1 out=ixxx2a;  
  by _Imputation_;  
  class TRTP;  
  monotone reg(M1= AHIBL PRFATBL AGE BMIBL);  
  mnar model(M1/modelobs= (TRTP='placebo'));  
  var AHIBL PRFATBL AGE BMIBL M1;  
run;
```

AD109 Pattern 2 and 3, and Placebo Pattern1 (dataset xxx2b):: Keep all except AD109 Pattern 1 missing M1

```
proc mi data=xxx2b seed=1719 nimpute=1 out=ixxx2b;  
  by _Imputation_;  
  class TRTP;  
  monotone reg(M1= TRTP AHIBL PRFATBL AGE BMIBL);  
  var TRTP AHIBL PRFATBL AGE BMIBL M1;  
run;
```

This document is confidential.

xxx3 is the combined data set ixxx2a (where TRTP='AD109') and ixxx2b;

Step 2: Impute missing value for M3

AD109 Pattern 1 (dataset xxx3a): Keep all AD109 participants from xxx3 with missing M3 with pattern 1 and all Placebo participants with non-missing M3

```
proc mi data=xxx3a seed=1720 nimpute=1 out=ixxx3a;  
  by _Imputation_;  
  class TRTP;  
  monotone reg(M3= AHIBL PRFATBL AGE BMIBL M1);  
  mnar model(M3/modelobs= (TRTP='placebo'));  
  var AHIBL PRFATBL AGE BMIBL M1 M3;  
run;
```

AD109 Pattern 2 and 3, and Placebo Pattern1 (dataset xxx3b): Keep all except AD109 Pattern 1 missing M3.

```
proc mi data=xxx3b seed=1721 nimpute=1 out=ixxx3b;  
  by _Imputation_;  
  class TRTP;  
  monotone reg(M3= TRTP AHIBL PRFATBL AGE BMIBL M1);  
  var TRTP AHIBL PRFATBL AGE BMIBL M1 M3;  
run;
```

xxx4 is the combined data set ixxx3a (where TRTP='AD109') and ixxx3b;

Step 3: Impute missing value for M6

AD109 Pattern 1 (dataset xxx4a): Keep all AD109 participants from xxx4 with missing M6 with pattern 1 and all Placebo participants with non-missing M6

```
proc mi data=xxx4a seed=1722 nimpute=1 out=ixxx4a;  
  by _Imputation_;  
  class TRTP;  
  monotone reg(M6= AHIBL PRFATBL AGE BMIBL M1 M3);  
  mnar model(M6/modelobs= (TRTP='placebo'));  
  var AHIBL PRFATBL AGE BMIBL M1 M3 M6;  
run;
```

AD109 Pattern 2 and 3, and Placebo Pattern1 (dataset xxx4b)::
Keep all except AD109 Pattern 1 missing M6.

This document is confidential.

```
proc mi data=xxx4b seed=1723 nimpute=1 out=ixxx4b;  
  by _Imputation_;  
  class TRTP;  
  monotone reg(M6= TRTP AHIBL PRFATBL AGE BMIBL M1 M3);  
  var TRTP AHIBL PRFATBL AGE BMIBL M1 M3 M6;  
run;
```

xxx5 is the combined data set ixxx4a (where TRTP='AD109') and ixxx4b;

15.2. Analysis Procedure

```
ods output lsmeans=ls diffs=diff;  
proc mixed data= DATAMI. Method=REML Empirical*;  
  by _imputation_;  
  class TRTP (ref="Placebo") USUBJID AHIGP AVISITN;  
  model CHG= TRTP AVISITN TRTP*AVISITN BASE AHIGP / s covb ddfm=kr;  
  repeated AVISITN / SUBJECT = USUBJID TYPE=UN;  
  lsmeans TRTP *AVISITN/DIFF CL;  
run;
```

Note: AHIGP is AH14 strata and BASE is baseline for the variable being analyzed.

Add option Empirical only (sandwich estimator) in case that TYPE=UN is not converge and TYPE=CS is used

```
*ls means;  
proc sort data=ls; by EFFECT AVISITN TRT01PN; run;  
ods output parameterestimates=rst_ls;  
proc mianalyze data=ls;  
  by EFFECT AVISITN TRTP;  
  modeleffects Estimate;  
  stderr stderr;  
run;
```

```
*ls mean diff and p-value;  
proc sort data=diff; by EFFECT AVISITN TRTP; run;  
ods output parameterestimates=rst_diff;  
proc mianalyze data=diff;  
  by EFFECT AVISITN TRTP;  
  modeleffects Estimate;  
  stderr stderr;  
run;
```

This document is confidential.

16. Example SAS Code for AHI4 Responder

16.1. Imputation Procedures

16.1.1. Non-monotone missing imputation

```
proc mi data=xxx1 seed=5879 nimpute=100 out=xxx2;  
  mcmc impute=monotone;  
  var TRTP AHIBL PRFATBL AGE BMIBL M1 M6;  
run;
```

TRTP=Treatment arm (active or placebo), AHIBL= Baseline AHI score, PRFATBL Baseline PROMIS Fatigue Raw Score, AGE=Age, BMI = Body Mass Index, M1 = AHI4 at Week 4, M6 = AHI4 at Week 26

16.1.2. Monotone Missing imputation

Note: `_imputation_` is imputation dataset reference ID created from Non-monotone imputation.

```
proc mi data=xxx2 seed=5880 nimpute=1 out=xxx3;  
  by _Imputation_;  
  class TRTP;  
  monotone reg(M1= TRTP AHIBL PRFATBL AGE BMIBL);  
  var TRTP AHIBL PRFATBL AGE BMIBL M1;  
run;
```

```
proc mi data=xxx3 seed=5881 nimpute=1 out=xxx4;  
  by _Imputation_;  
  class TRTP;  
  monotone reg(M6= TRTP AHIBL PRFATBL AGE BMIBL M1);  
  var TRTP AHIBL PRFATBL AGE BMIBL M1 M6;  
run;
```

16.2. Analysis Procedure

*calculate the of responder;

```
Data temp;  
  Set yyy;  
  if PCHG^=. then do;  
    if PCHG<-50 then RESPNDEF=1;  
    else RESPNDEF=2;  
  end;  
run;
```

This document is confidential.

*calculate the proportion of responder for each group;

```
proc freq data=temp;
  by _imputation_ TRTP;
  tables RESPNDEF /cl binomial(level=1);
  ods output Binomial=prop;
run;

data prop_trt;
  merge prop( where=(label1="Proportion") keep = _imputation_ TRTP NVALUE1 label1
  rename=(NVALUE1=prop)) prop( where=(label1="ASE") keep = _imputation_ TRTP
  NVALUE1 label1 rename=(NVALUE1=prop_se));
  by _imputation_ TRTP;
run;
proc sort data=prop_trt; by TRTP _imputation_; run;
proc mianalyze data=prop_trt;
  modeleffects prop;
  stderr prop_se;
  by TRTP;
  ods output parameterestimates =rst_prop;
run;
```

*calculate the difference with 95% CI of responder proportion between AD109 vs Placebo;

```
ods output parameterestimates =rst_prop_diff;
run;
proc freq data=temp;
  by _imputation_;
  tables STRATUM *TRTP* RESPNDEF /cmh RISKDIFF(COMMON Column=2);
  ods output CommonPdiff=Pdiff CommonRelRisks=or CMH=cmh;
run;
```

Note: need to specify column=2 if responder is the 2nd value of RESPNDEF (eg. Y vs N).

* Combined adjusted proportion difference from 100 imputed outputs;

```
proc mianalyze data= Pdiff (where=(METHOD=" Mantel-Haenszel"));
  modeleffects VALUE;
  stderr STDERR;
  ods output parameterestimates =rst_prop_diff_adj;
run;
```

*Combined P value;

This document is confidential.

```
data cmh_wh;
  set cmh(WHERE=(AltHypothesis="General Association"));
  cmh_value_wh=((VALUE/DF)**(1/3) - (1-2/(9*DF)))/SQRT(2/(9*DF));
  cmh_sterr_wh = 1.0;
run;

proc mianalyze data=cmh_wh;
  modeleffects cmh_value_wh;
  stderr cmh_sterr_wh;
  ods output parameterestimates =p_value;
run;
```

This document is confidential.

17. Appendix 1: Adverse Event of Special Interest List of FMQs and PTs

AESI	Search Strategy			Comments
	FMQs ¹	Customized Medical Query (CMQ)	Single Preferred Term	
Urinary hesitation	NA	Propose to group the following 3 PTs: • Urinary hesitation • Urine flow decreased • Urine output decreased	NA	Urinary retention is clinically different from urinary hesitation and the Sponsor proposes not to combine and to present AE data separately
Urinary retention	• Urinary retention (narrow and broad)		NA	
Liver Injury	• Hepatic Failure (narrow and board) • Hepatic Injury (narrow and board)			The Sponsor is including these FMQs per FDA ISS Type C Meeting written response dated 08Jan2025
Cardiovascular	• Hypotension Group includes the following FMQs: ○ Syncope (narrow and broad) ○ dizziness (narrow) ○ hypotension (narrow) • Palpitations Group includes the following FMQs: ○ palpitations (narrow)	NA	NA	

This document is confidential.

Search Strategy				
AESI	FMQs ¹	Customized Medical Query (CMQ)	Single Preferred Term	Comments
	○ Tachycardia (narrow) • Myocardial ischemia (narrow and broad) • Systemic Hypertension (narrow) • Stroke and TIA (narrow)			
Suicidal ideation	• Self-harm (narrow and broad)	NA	NA	
Daytime sleepiness	• Somnolence (Narrow and broad)	NA	NA	
Motor vehicle accidents	NA	NA	Road Traffic Accident	
Anticholinergic effects	NA	4 FMQs • Confusional state (narrow), • constipation (narrow and broad), • psychosis (narrow and broad), • nausea (narrow) PTs • blurred vision • memory impairment	NA	The Sponsor is proposing to combine 4 FMQs and 2 PTs to represent the medical concept of anticholinergic effects that are not cardiac in nature

This document is confidential.

AESI	Search Strategy			Comments
	FMQs ¹	Customized Medical Query (CMQ)	Single Preferred Term	
Psychiatric disorders	- mania (narrow and broad) - psychosis (narrow and broad)			

¹ FMQs are based on the 2022 FDA list (https://downloads.regulations.gov/FDA-2022-N-1961-0001/attachment_1.xlsm)

Some AE terms are counted to 2 FMQs in below tables; the term in green box will be considered when assigning AESI categories:

	AEDECOD	CMQ	_NAME_	FMQ01	FMQ02
1	Delirium	Anticholinergic effects	FMQ	Confusional State (narrow)	Psychosis (narrow and broad)
2	Dizziness	Cardiovascular	FMQ	Dizziness (narrow)	Syncopal (narrow and broad)
3	Hypotension	Cardiovascular	FMQ	Hypotension (narrow)	Syncopal (narrow and broad)
4	Hypotension postural aggravated	Cardiovascular	FMQ	Hypotension (narrow)	Syncopal (narrow and broad)
5	Intensive care unit delirium	Anticholinergic effects	FMQ	Confusional State (narrow)	Psychosis (narrow and broad)
6	Neonatal hypotension	Cardiovascular	FMQ	Hypotension (narrow)	Syncopal (narrow and broad)
7	Orthostatic hypotension	Cardiovascular	FMQ	Hypotension (narrow)	Syncopal (narrow and broad)
8	Postural hypotension	Cardiovascular	FMQ	Hypotension (narrow)	Syncopal (narrow and broad)
9	Presyncope	Cardiovascular	FMQ	Dizziness (narrow)	Syncopal (narrow and broad)
10	Procedural hypotension	Cardiovascular	FMQ	Hypotension (narrow)	Syncopal (narrow and broad)
11	Vasovagal attack	Cardiovascular	FMQ	Dizziness (narrow)	Syncopal (narrow and broad)
12	Ventricular tachycardia	Cardiovascular	FMQ	Myocardial ischemia (narrow and broad)	Tachycardia (narrow)

This document is confidential.

APC-APN-305_statistical analysis plan_v2.0 22Apr2025_Final_Clean

Final Audit Report

2025-04-22

Created:	2025-04-22
By:	Shuhong Zhao (shuhong.zhao@syneoshealth.com)
Status:	Signed
Transaction ID:	CBJCHBCAABAASnhTQT6XjcuOn1WKb_D8S9Xq9gzMjTij
Documents:	APC-APN-305_statistical analysis plan_v2.0 22Apr2025_Final_Clean.docx (75 pages)
Number of Documents:	1
Document page count:	75
Number of supporting files:	0
Supporting files page count:	0

"APC-APN-305_statistical analysis plan_v2.0 22Apr2025_Final_Clean" History



Document created by Shuhong Zhao (shuhong.zhao@syneoshealth.com)

Documents: APC-APN-305_statistical analysis plan_v2.0 22Apr2025_Final_Clean.docx
2025-04-22 - 6:43:33 PM GMT- IP address: 20.62.212.46



Document emailed to Shuhong Zhao (shuhong.zhao@syneoshealth.com) for signature

2025-04-22 - 6:45:05 PM GMT



Agreement viewed by Shuhong Zhao (shuhong.zhao@syneoshealth.com)

Documents: APC-APN-305_statistical analysis plan_v2.0 22Apr2025_Final_Clean.docx
2025-04-22 - 6:45:05 PM GMT- IP address: 20.62.212.46



Document e-signed by Shuhong Zhao (shuhong.zhao@syneoshealth.com)

Documents: APC-APN-305_statistical analysis plan_v2.0 22Apr2025_Final_Clean.docx
Signing reason: I am the author
Signature Date: 2025-04-22 - 6:45:56 PM GMT - Time Source: server- IP address: 20.62.212.46



Shuhong Zhao (shuhong.zhao@syneoshealth.com) authenticated with Adobe Acrobat Sign.

Challenge: The user completed the signing ceremony.
2025-04-22 - 6:45:56 PM GMT



Document emailed to Jianping He (jianping.he@syneoshealth.com) for signature

2025-04-22 - 6:45:59 PM GMT

 Email viewed by Jianping He (jianping.he@syneoshealth.com)

2025-04-22 - 7:06:38 PM GMT- IP address: 104.47.73.254

 Agreement viewed by Jianping He (jianping.he@syneoshealth.com)

Documents: APC-APN-305_statistical analysis plan_v2.0 22Apr2025_Final_Clean.docx

2025-04-22 - 7:07:00 PM GMT- IP address: 136.226.69.0

 Jianping He (jianping.he@syneoshealth.com) authenticated with Adobe Acrobat Sign.

Challenge: The user completed the signing ceremony.

2025-04-22 - 7:09:31 PM GMT

 Document e-signed by Jianping He (jianping.he@syneoshealth.com)

Documents: APC-APN-305_statistical analysis plan_v2.0 22Apr2025_Final_Clean.docx

Signing reason: I am the reviewer

Signature Date: 2025-04-22 - 7:09:32 PM GMT - Time Source: server- IP address: 136.226.69.0

 Document emailed to Brian Mangal (bmangal@gmail.com) for signature

2025-04-22 - 7:09:39 PM GMT

 Email viewed by Brian Mangal (bmangal@gmail.com)

2025-04-22 - 7:38:57 PM GMT- IP address: 66.249.84.165

 Brian Mangal (bmangal@gmail.com) authenticated with Adobe Acrobat Sign.

Challenge: The user opened the agreement.

2025-04-22 - 7:39:11 PM GMT

 Agreement viewed by Brian Mangal (bmangal@gmail.com)

Documents: APC-APN-305_statistical analysis plan_v2.0 22Apr2025_Final_Clean.docx

2025-04-22 - 7:39:12 PM GMT- IP address: 173.180.25.216

 Document e-signed by Brian Mangal (bmangal@gmail.com)

Documents: APC-APN-305_statistical analysis plan_v2.0 22Apr2025_Final_Clean.docx

Signing reason: I am the approver

Signature Date: 2025-04-22 - 7:39:37 PM GMT - Time Source: server- IP address: 173.180.25.216

 Brian Mangal (bmangal@gmail.com) authenticated with Adobe Acrobat Sign.

Challenge: The user completed the signing ceremony.

2025-04-22 - 7:39:37 PM GMT

 Document emailed to Ron Farkas (rfarkas@apnimed.com) for signature

2025-04-22 - 7:39:40 PM GMT

 Email viewed by Ron Farkas (rfarkas@apnimed.com)

2025-04-22 - 7:39:47 PM GMT- IP address: 13.217.233.228

- ✓ Ron Farkas (rfarkas@apnimed.com) authenticated with Adobe Acrobat Sign.
Challenge: The user opened the agreement.
2025-04-22 - 7:40:35 PM GMT
- 📄 Agreement viewed by Ron Farkas (rfarkas@apnimed.com)
Documents: APC-APN-305_statistical analysis plan_v2.0 22Apr2025_Final_Clean.docx
2025-04-22 - 7:40:38 PM GMT- IP address: 100.18.7.250
- ✍️ Document e-signed by Ron Farkas (rfarkas@apnimed.com)
Documents: APC-APN-305_statistical analysis plan_v2.0 22Apr2025_Final_Clean.docx
Signing reason: I am the approver
Signature Date: 2025-04-22 - 7:41:14 PM GMT - Time Source: server- IP address: 100.18.7.250
- ✓ Ron Farkas (rfarkas@apnimed.com) authenticated with Adobe Acrobat Sign.
Challenge: The user completed the signing ceremony.
2025-04-22 - 7:41:14 PM GMT
- ✉️ Document emailed to Luigi Taranto Montemurro (ltaranto@apnimed.com) for signature
2025-04-22 - 7:41:21 PM GMT
- 📄 Email viewed by Luigi Taranto Montemurro (ltaranto@apnimed.com)
2025-04-22 - 7:41:30 PM GMT- IP address: 13.218.159.22
- ✓ Luigi Taranto Montemurro (ltaranto@apnimed.com) authenticated with Adobe Acrobat Sign.
Challenge: The user opened the agreement.
2025-04-22 - 7:49:58 PM GMT
- 📄 Agreement viewed by Luigi Taranto Montemurro (ltaranto@apnimed.com)
Documents: APC-APN-305_statistical analysis plan_v2.0 22Apr2025_Final_Clean.docx
2025-04-22 - 7:50:01 PM GMT- IP address: 50.255.181.5
- ✓ Luigi Taranto Montemurro (ltaranto@apnimed.com) authenticated with Adobe Acrobat Sign.
Challenge: The user completed the signing ceremony.
2025-04-22 - 7:51:01 PM GMT
- ✍️ Document e-signed by Luigi Taranto Montemurro (ltaranto@apnimed.com)
Documents: APC-APN-305_statistical analysis plan_v2.0 22Apr2025_Final_Clean.docx
Signing reason: I am the approver
Signature Date: 2025-04-22 - 7:51:02 PM GMT - Time Source: server- IP address: 50.255.181.5
- ✓ Agreement completed.
2025-04-22 - 7:51:02 PM GMT